deferiprone has been researched along with Anemia, Cooley's in 276 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 10.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| " Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications." | 9.15 | Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. ( Akrawinthawong, K; Chaowalit, N; Chatuparisuth, T; Siritanaratkul, N, 2011) |
| "Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients." | 9.12 | Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. ( Capra, M; Cracolici, E; De Marchi, D; Lombardi, M; Maggio, A; Malizia, R; Midiri, M; Pepe, A; Positano, V; Prossomariti, L, 2006) |
| "Deferiprone (L1) has been recommended as an effective oral chelation therapy for patients with beta-thalassemia major (TM)." | 9.12 | Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. ( Hsiao, CC; Jang, RC; Liang, DC; Peng, CT; Wang, LY; Wu, KH; Wu, SF; Yang, CP, 2006) |
| "Deferiprone is a safe and effective oral iron-chelating agent which can be used, under strict supervision, in transfusion-dependent iron overloaded children." | 9.09 | A trial of deferiprone in transfusion-dependent iron overloaded children. ( De Silva, DD; Fernandopulle, M; Fonseka, EA; Lucas, GN; Perera, BJ, 2000) |
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 8.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| " Children with thalassemia between 2 and 18 y of age with serum ferritin above 1500 ng/ml were started on oral deferiprone and deferasirox." | 8.02 | Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. ( Delhikumar, CG; DivakarJose, RR; Ram Kumar, G, 2021) |
| "The present study failed to demonstrate that the use of deferiprone at >90 mg/kg/d was associated with increased risk of agranulocytosis or neutropenia, but did demonstrate more effective liver iron control in iron overload patients." | 7.91 | Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload. ( Binding, A; Kuo, KHM; Tomlinson, G; Ward, R, 2019) |
| "A 29-year-old male with transfusion-dependent β-thalassemia major (β-TM), splenectomized and on chelation therapy with deferiprone (DFP or L1) due to heart and liver hemosiderosis, presented with high fever and agranulocytosis." | 7.83 | A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone. ( Apostolou, C; Klonizakis, P; Kotsiafti, A; Mainou, M; Psarras, K; Soulountsi, V; Vlachaki, E, 2016) |
| "Approximately 6% of patients with thalassemia receiving deferiprone develop neutropenia." | 7.80 | Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. ( Chan, LL; El-Alfy, MS; El-Beshlawy, AM; Sari, TT; Tricta, F, 2014) |
| "There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction." | 7.76 | Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. ( Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V, 2010) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 7.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "Cardiac events and death are not uncommon in adults with beta-thalassemia (b-TM) taking deferoxamine (DFO) monotherapy because of poor compliance and possibly the less effectiveness of DFO in controlling cardiac iron overload." | 7.76 | Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. ( Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS, 2010) |
| "The potential of free radical formation in serum of beta-thalassemia/Hb E patients receiving a single oral dose of 25 mg/kg body weight of deferiprone, a bidentate orally active iron chelator, was evaluated using EPR/spin trapping technique." | 7.75 | Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia. ( Chantharaksri, U; Fucharoen, S; Jirasomprasert, T; Limenta, LM; Morales, NP; Sirijaroonwong, S; Wilairat, P; Yamanont, P, 2009) |
| " Deferiprone is one of a few drugs that are routinely used in medicine for the treatment of iron overload in thalassemic patients." | 7.75 | Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. ( Abrol, P; Sen, R; Sharma, RK; Tewari, S, 2009) |
| "Variable response to deferiprone has been observed in the management of iron overload in patients with thalassemia major." | 7.74 | Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major. ( Girisha, KM; Goel, H; Phadke, SR, 2008) |
| "This study was undertaken to describe the radiographic and MRI appearances of arthropathy of the knees in 14 patients with beta-thalassemia major undergoing chelation therapy with deferiprone (L1)." | 7.72 | Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia. ( Babyn, PS; Di Gennaro, L; Eber, SW; Kellenberger, CJ; Saurenmann, T; Schmugge, M; Willi, UV, 2004) |
| "A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment." | 7.69 | Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). ( Castriota-Scanderbeg, A; Sacco, M, 1997) |
| "Iron overload is a common complication experienced by transfusion-dependent children with hemoglobin disorders." | 7.01 | No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis. ( Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E, 2023) |
| "DFP/DFX combination proved superior in improving cardiac T2*, treatment compliance, and patients satisfaction with no greater adverse events." | 6.80 | Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. ( Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y, 2015) |
| "Deferiprone use was associated with a significant decline in mean serum ferritin level from 2532±1463 μg/L at baseline to 2176±1144 μg/L (P<0." | 6.75 | The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| "Deferiprone monotherapy was significantly more effective than deferoxamine over 1 year in improving asymptomatic myocardial siderosis in beta-thalassemia major." | 6.72 | Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. ( Aessopos, A; Berdoukas, V; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Smith, GC; Tanner, MA; Westwood, MA; Wonke, B, 2006) |
| "Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM)." | 6.72 | Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. ( Daar, S; Pathare, AV, 2006) |
| "Patients with thalassemia major require lifelong chelation therapy to prevent iron-induced organ damage." | 6.70 | Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. ( Cohen, AR; Dhillon, AP; Galanello, R; Gamberini, MR; Guido, M; Piga, A; Schwartz, E; Sweeney, G; Wanless, IR, 2002) |
| " Adverse effects of DFP were nausea and vomiting (30%), significant arthropathy requiring stopping of the drug (30%), and reversible neutropenia in one patient." | 6.68 | Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia. ( Adhikari, D; Basu, AK; Bhattacharya, B; Biswas, A; Chakraborty, ML; Chandra, S; Maitra, TK; Roy, TB, 1995) |
| "Deferiprone was more efficacious than DFO in improving cardiac ejection fraction [MD 2." | 6.50 | A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. ( Kuo, KH; Mrkobrada, M, 2014) |
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 6.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| "We concluded that pregnancy is not a contraindication in beta-thalassemia major; complex individual care is needed to achieve a safe outcome for the mother." | 5.51 | A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy. ( Abu, MA; Ahmad, MF; Arsad, N; Chew, KT; Omar, MH; Shafiee, MN; Zakaria, NZ, 2019) |
| "Deferasirox is an oral chelator." | 5.46 | Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017) |
| "In our study, chelation treatment during pregnancy did not prevent the delivery of healthy children." | 5.43 | Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? ( Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E, 2016) |
| "Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy." | 5.37 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011) |
| "Beta-thalassemia major (beta-TM), patients, asymptomatic and with preserved left ventricular ejection fraction (LVEF) were studied echocardiographically." | 5.36 | Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients. ( Farmaki, K; Fragatou, S; Kremastinos, D; Kyrzopoulos, S; Paraskevaidis, I; Tsiapras, D; Voudris, V, 2010) |
| "Five thalassemia major (TM) patients who were undergoing chelation monotherapy with DFO were enrolled." | 5.35 | Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia. ( Aessopos, A; Assimakopoulos, G; Polonofi, K; Rigaki, K; Tsironi, M, 2008) |
| "In paediatric patients with transfusion-dependent haemoglobinopathies, deferiprone was effective and safe in inducing control of iron overload during 12 months of treatment." | 5.34 | Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. ( Bejaoui, M; Bonifazi, D; Ceci, A; Christou, S; Cosmi, C; Cuccia, L; Del Vecchio, GC; Della Pasqua, O; El-Beshlawy, A; Felisi, M; Filosa, A; Hassab, H; Kattamis, A; Kreka, M; Maggio, A; Origa, R; Putti, MC; Reggiardo, G; Sherief, L; Spino, M; Telfer, P; Tempesta, B; Tricta, F; Tsang, YC; Vitrano, A; Zaka, A, 2020) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 5.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "Three iron chelators are used to treat transfusion-dependent beta-thalassemia: desferrioxamine (DFO), deferasirox (DFX), and deferiprone (DFP)." | 5.30 | Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study. ( Chen, X; Hsieh, YW; Lin, CH; Peng, CT; Song, TS; Weng, TF; Wu, CC; Wu, KH, 2019) |
| "was to study the therapeutic value of combined therapy of Deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia with iron overload'." | 5.20 | Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major. ( Abd El-Lateef, AE; Elfaragy, MS; Elrifaey, SM; Hagag, AA, 2015) |
| " Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications." | 5.15 | Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. ( Akrawinthawong, K; Chaowalit, N; Chatuparisuth, T; Siritanaratkul, N, 2011) |
| "The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients > or =2 yr with beta-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone." | 5.14 | Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. ( Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A, 2009) |
| " In 18 requiring thyroxine supplementation for hypothyroidism, 10 were able to discontinue, and four reduced their thyroxine dose." | 5.14 | Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. ( Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I, 2010) |
| "In patients with severe myocardial siderosis and impaired LV function, combined chelation therapy with subcutaneous deferoxamine and oral deferiprone reduces myocardial iron and improves cardiac function." | 5.13 | Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. ( Agus, A; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Pibiri, M; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA, 2008) |
| "Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients." | 5.12 | Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. ( Capra, M; Cracolici, E; De Marchi, D; Lombardi, M; Maggio, A; Malizia, R; Midiri, M; Pepe, A; Positano, V; Prossomariti, L, 2006) |
| "Deferiprone (L1) has been recommended as an effective oral chelation therapy for patients with beta-thalassemia major (TM)." | 5.12 | Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. ( Hsiao, CC; Jang, RC; Liang, DC; Peng, CT; Wang, LY; Wu, KH; Wu, SF; Yang, CP, 2006) |
| " We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications." | 5.12 | Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006) |
| "The main adverse effect of deferiprone is the development of neutropenia, which occurs via an unknown mechanism." | 5.12 | Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. ( Athanassiou-Metaxa, M; Haralambidou-Vranitsa, S; Ioannidou-Papagiannaki, E; Klonizakis, I; Perifanis, V; Tziomalos, K; Vlachaki, E, 2007) |
| " We characterized NTBI's susceptibility to deferoxamine (directly chelatable iron [DCI]) and redox activity (labile plasma iron [LPI]) during the course of long-term, continuous L1 (deferiprone) treatment of patients with hemoglobin E disease and beta-thalassemia (n = 17)." | 5.11 | Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. ( Breuer, W; Cabantchik, ZI; Hershko, C; Pootrakul, P; Sametband, M; Sirankapracha, P, 2004) |
| "The purpose of our study was to evaluate the effectiveness and safety of combined therapy with deferoxamine (DFO) and deferiprone (DFP) in patients with beta-thalassemia major and increased serum ferritin." | 5.11 | Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. ( Alymara, V; Bouranta, P; Bourantas, D; Bourantas, KL; Chaidos, A; Gouva, M; Tzouvara, E; Vassou, A, 2004) |
| "The purpose of this study was to evaluate if the variations of heart magnetic resonance imaging in beta-thalassemia major patients treated with Deferoxamine B mesylate (DF) or Deferiprone (L1) chelation therapy is a useful tool of the indirect myocardial iron content determination." | 5.10 | Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. ( Bartolotta, V; Borsellino, Z; Capra, M; D'Ascola, DG; Galia, M; Gerardi, C; Maggio, A; Magnano, C; Malizia, R; Mangiagli, A; Midiri, M; Morabito, A; Rigano, P; Rizzo, M, 2003) |
| "Deferiprone is a safe and effective oral iron-chelating agent which can be used, under strict supervision, in transfusion-dependent iron overloaded children." | 5.09 | A trial of deferiprone in transfusion-dependent iron overloaded children. ( De Silva, DD; Fernandopulle, M; Fonseka, EA; Lucas, GN; Perera, BJ, 2000) |
| "Deferiprone is an orally active iron-chelating agent that is being evaluated as a treatment for iron overload in thalassemia major." | 5.08 | Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. ( Brittenham, GM; Burt, AD; Cameron, RG; Fleming, KA; McClelland, RA; McLaren, CE; Olivieri, NF; Templeton, DM, 1998) |
| "Iron chelating agents - deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX) - are used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to siderosis." | 4.93 | Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. ( El Rassi, F; Saliba, AN; Taher, AT, 2016) |
| "Deferiprone (DFP), the first oral iron chelator, has been used in patients with beta-thalassemia major to reduce serum ferritin levels and total iron burden, leading to decreased cardiac iron levels." | 4.84 | Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature. ( Perifanis, V; Tsatra, I; Tsayas, I; Tselios, K; Vlachaki, E, 2008) |
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 4.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| " As LPI is detected primarily in patients with transfusional iron overload and other forms of hemosiderosis, we review here regimens of iron chelation with deferrioxamine and deferiprone (separately or combined) in terms of their efficacy in minimizing daily exposure to LPI in thalassemia major and thalassemia intermedia patients." | 4.82 | LPI-labile plasma iron in iron overload. ( Breuer, W; Cabantchik, ZI; Cianciulli, P; Zanninelli, G, 2005) |
| " In this report, we describe two pediatric patients diagnosed with nephrolithiasis while undergoing treatment with the chelating agents deferasirox, deferiprone, and deferoxamine for iron overload secondary to repeat blood transfusion." | 4.31 | Nephrolithiasis in two patients on iron chelation therapy: A case report. ( Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y, 2023) |
| " Children with thalassemia between 2 and 18 y of age with serum ferritin above 1500 ng/ml were started on oral deferiprone and deferasirox." | 4.02 | Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. ( Delhikumar, CG; DivakarJose, RR; Ram Kumar, G, 2021) |
| "Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and deferiprone." | 3.91 | Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. ( Gallie, BL; Olivieri, NF; Sabouhanian, A, 2019) |
| "The present study failed to demonstrate that the use of deferiprone at >90 mg/kg/d was associated with increased risk of agranulocytosis or neutropenia, but did demonstrate more effective liver iron control in iron overload patients." | 3.91 | Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload. ( Binding, A; Kuo, KHM; Tomlinson, G; Ward, R, 2019) |
| "A 20-year-old male affected by transfusion-dependent β-thalassemia (β-thal), was prescribed intensive chelation therapy with deferoxamine (DFO) and deferiprone (DFP) because of severe hepatic and cardiac iron overload and β-blocker and warfarin to manage a previous event of atrial fibrillation (AFib) and heart failure." | 3.88 | Life-Threatening Drug-Induced Liver Injury in a Patient with β-Thalassemia Major and Severe Iron Overload on Polypharmacy. ( Casale, M; Cerasari, G; Corvino, F; Perrotta, S; Persico, M; Picariello, S; Rossi, F; Scianguetta, S, 2018) |
| "A 29-year-old male with transfusion-dependent β-thalassemia major (β-TM), splenectomized and on chelation therapy with deferiprone (DFP or L1) due to heart and liver hemosiderosis, presented with high fever and agranulocytosis." | 3.83 | A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone. ( Apostolou, C; Klonizakis, P; Kotsiafti, A; Mainou, M; Psarras, K; Soulountsi, V; Vlachaki, E, 2016) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| "Approximately 6% of patients with thalassemia receiving deferiprone develop neutropenia." | 3.80 | Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. ( Chan, LL; El-Alfy, MS; El-Beshlawy, AM; Sari, TT; Tricta, F, 2014) |
| "Deferiprone is used as a chelation agent in chronic iron overload in β-thalassemia patients." | 3.79 | Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients. ( Dadheech, S; Hussien, MD; Jain, S; Jyothy, A; Munshi, A; Rao, AV; Shaheen, U, 2013) |
| "There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction." | 3.76 | Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. ( Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V, 2010) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 3.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "Cardiac events and death are not uncommon in adults with beta-thalassemia (b-TM) taking deferoxamine (DFO) monotherapy because of poor compliance and possibly the less effectiveness of DFO in controlling cardiac iron overload." | 3.76 | Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. ( Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS, 2010) |
| "The potential of free radical formation in serum of beta-thalassemia/Hb E patients receiving a single oral dose of 25 mg/kg body weight of deferiprone, a bidentate orally active iron chelator, was evaluated using EPR/spin trapping technique." | 3.75 | Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia. ( Chantharaksri, U; Fucharoen, S; Jirasomprasert, T; Limenta, LM; Morales, NP; Sirijaroonwong, S; Wilairat, P; Yamanont, P, 2009) |
| " Deferiprone is one of a few drugs that are routinely used in medicine for the treatment of iron overload in thalassemic patients." | 3.75 | Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. ( Abrol, P; Sen, R; Sharma, RK; Tewari, S, 2009) |
| "Our previous study showed that combined therapy with deferiprone (L1) and deferoxamine (DFO) was safe and efficacious in reducing iron overload in poorly-chelated thalassemia major patients for the short-term but the magnetic resonance imaging (MRI) T2* evaluation was not available at that time." | 3.75 | A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*. ( Chan, GC; Cheuk, DK; Chiang, AK; Chu, WC; Ha, SY; Ho, MH; Mok, AS; Raskalkar, DD, 2009) |
| "Variable response to deferiprone has been observed in the management of iron overload in patients with thalassemia major." | 3.74 | Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major. ( Girisha, KM; Goel, H; Phadke, SR, 2008) |
| "Herein we present a 7-year-old beta-thalassemia major patient who developed severe Henoch-Schönlein purpura (HSP) with renal, pulmonary involvement and invagination while under iron chelation with deferiprone." | 3.74 | Severe Henoch-Schönlein purpura in a thalassemic patient under deferiprone treatment. ( Besbas, N; Gücer, S; Gümrük, F; Kale, G; Ozen, S; Unal, S, 2008) |
| "Combination chelation therapy with desferrioxamine and deferiprone has recently been suggested as a more effective tissue iron-chelating treatment for transfusion-dependent beta-thalassemia patients, although a standard dosage protocol has not yet been established." | 3.74 | Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine. ( Aessopos, A; Deftereos, S; Farmakis, D; Kati, M; Polonifi, E; Tsironi, M, 2007) |
| " However, other factors may also have similar effects such as the level of iron overload, chronic immuno-stimulation due to transfusions, splenectomy and deferoxamine (DFO)." | 3.74 | Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment. ( Athanassiou-Metaxa, M; Economou, M; Kanakoudi-Tsakalidou, F; Perifanis, V; Taparkou, A; Tourkantoni, N; Tzimouli, V; Zafiriou, D, 2008) |
| "New measures of iron accumulation in liver and heart (superconducting quantum inference device and magnetic resonance imaging), and oral iron chelators (deferiprone and deferasirox) are available for managing iron overload in thalassemia major." | 3.74 | Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. ( Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S, 2008) |
| " In thalassemia major patients, combined therapy with desferrioxamine and deferiprone has maximized tissue iron removal and may reduce the overall occurrence of hemosiderotic heart failure." | 3.73 | Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia. ( Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Moyssakis, I; Polonifi, K; Tsironi, M, 2005) |
| "We used combined therapy with desferrioxamine and deferiprone to treat 79 patients with severe iron overload (serum ferritin higher than 3000 ng/mL) who had low compliance with subcutaneous desferrioxamine." | 3.73 | Combined therapy with deferiprone and desferrioxamine in thalassemia major. ( Agus, A; Bina, P; Crobu, G; Defraia, E; Dessì, C; Galanello, R; Leoni, G; Muroni, PP; Origa, R, 2005) |
| "Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major." | 3.73 | Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006) |
| "This study was undertaken to describe the radiographic and MRI appearances of arthropathy of the knees in 14 patients with beta-thalassemia major undergoing chelation therapy with deferiprone (L1)." | 3.72 | Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia. ( Babyn, PS; Di Gennaro, L; Eber, SW; Kellenberger, CJ; Saurenmann, T; Schmugge, M; Willi, UV, 2004) |
| "In previous trials, the orally active iron chelator deferiprone (L1) has been associated with sporadic agranulocytosis, milder forms of neutropenia and other side-effects." | 3.70 | Safety profile of the oral iron chelator deferiprone: a multicentre study. ( Cohen, AR; Dipalma, A; Galanello, R; Piga, A; Tricta, F; Vullo, C, 2000) |
| "A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment." | 3.69 | Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). ( Castriota-Scanderbeg, A; Sacco, M, 1997) |
| "Iron overload is a common complication experienced by transfusion-dependent children with hemoglobin disorders." | 3.01 | No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis. ( Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E, 2023) |
| "2 mg · h/mL, and mean Cmax ± SD was found to be 10." | 2.82 | Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β-Thalassemia. ( Bellanti, F; Danhof, M; Della Pasqua, O; Di Iorio, VL, 2016) |
| "Enrolled patients (9 with β-thalassemia major and 33 with β-thalassemia hemoglobin E), ranging from 3 to 18 years in age, were divided into 3 groups; group 1 ferritin ≥1,000-2,500 ng/ml (n = 10), group 2 ferritin >2,500-4,000 ng/ml (n = 23) and group 3 ferritin >4,000 ng/ml (n = 9)." | 2.80 | Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience. ( Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Sungkarat, W; Wongwerawattanakoon, P, 2015) |
| "DFP/DFX combination proved superior in improving cardiac T2*, treatment compliance, and patients satisfaction with no greater adverse events." | 2.80 | Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. ( Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y, 2015) |
| "Neutropenia and agranulocytosis were also detected, suggesting needing of strict hematological control." | 2.80 | Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. ( Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A, 2015) |
| "Treatment with deferasirox significantly improves left ventricular function." | 2.77 | Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. ( Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L, 2012) |
| "Deferiprone was rapidly absorbed and reached maximum concentration (C(max)) within 1 h after administration." | 2.77 | Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients. ( Chantraraksri, U; Fucharoen, S; Morales, NP; Rodrat, S; Tankanitlert, J; Yamanont, P, 2012) |
| "In β-thalassemia major (β-TM) patients, iron chelation therapy is mandatory to reduce iron overload secondary to transfusions." | 2.76 | Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients. ( Argento, C; Campisi, S; Capra, M; Caruso, V; Cianciulli, P; Cuccia, L; D'Amico, G; D'Ascola, DG; Fidone, C; Filosa, A; Gagliardotto, F; Gerardi, C; Gluud, C; Maggio, A; Magnano, C; Malizia, R; Morabito, A; Pantalone, GR; Pepe, A; Prossomariti, L; Quota, A; Rigano, P; Rizzo, M; Romeo, MA; Violi, P; Vitrano, A, 2011) |
| "We evaluated 36 patients affected by thalassemia major treated with combined chelation therapy." | 2.75 | Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Matola, T; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "Deferiprone use was associated with a significant decline in mean serum ferritin level from 2532±1463 μg/L at baseline to 2176±1144 μg/L (P<0." | 2.75 | The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| "A total of 70 transfusion-dependent thalassemia major patients were randomly selected to receive one of the following two treatments: deferiprone in combination with desferrioxamine (n=35, desferrioxamine+deferiprone group) or desferrioxamine alone (n=35, desferrioxamine-only group)." | 2.74 | Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia. ( Cohan, N; Haghpanah, S; Jabbari, A; Zareifar, S, 2009) |
| "A total of 24 patients with thalassemia major were randomized to receive one of the following two treatments; DFP given at a daily dose of 75 mg/kg in combination with DFO (40-50 mg/kg twice weekly) (n=12) or as single agent (n=12)." | 2.73 | A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. ( Aydinok, Y; Cetiner, N; Ellis, G; Manz, C; Nart, D; Terzi, A; Ulger, Z; Zimmermann, A, 2007) |
| "Deferiprone monotherapy was significantly more effective than deferoxamine over 1 year in improving asymptomatic myocardial siderosis in beta-thalassemia major." | 2.72 | Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. ( Aessopos, A; Berdoukas, V; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Smith, GC; Tanner, MA; Westwood, MA; Wonke, B, 2006) |
| "Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM)." | 2.72 | Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. ( Daar, S; Pathare, AV, 2006) |
| " We conclude that the short-term use of L1, with or without DFO, was safe and efficacious in our Chinese patient cohort." | 2.72 | A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. ( Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO, 2006) |
| "The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x 10(9)/L) and milder forms of neutropenia (ANC, 500-1500 x 10(9)/L) were 0." | 2.71 | Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. ( Cohen, AR; De Sanctis, V; Galanello, R; Piga, A; Tricta, F, 2003) |
| "Measurements of chromosomal aberrations were made in 10 thalassaemia major patients treated long-term with deferiprone (at least 5 years) and compared with an equal number of patients matched for age, sex and iron overload, treated long-term with deferoxamine." | 2.71 | Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study. ( Galanello, R; Kirkland, D; Leoni, G; Marshall, R; Minto, S; Spino, M; Tricta, F, 2003) |
| "Deferiprone was given at a dose of 75 mg/kg daily for 12 months." | 2.71 | Deferiprone as an oral iron chelator in sickle cell disease. ( Douskou, M; Loukopoulos, D; Meletis, J; Ourailidis, A; Papassotiriou, I; Stamoulakatou, A; Terpos, E; Voskaridou, E, 2005) |
| "Patients with thalassemia major require lifelong chelation therapy to prevent iron-induced organ damage." | 2.70 | Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. ( Cohen, AR; Dhillon, AP; Galanello, R; Gamberini, MR; Guido, M; Piga, A; Schwartz, E; Sweeney, G; Wanless, IR, 2002) |
| " These data show that the drug was effective in reducing serum ferritin levels and the incidence of adverse events was not greater than the frequency reported in clinical trials." | 2.70 | The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. ( Baiardi, P; Cappellini, MD; Carnelli, V; Ceci, A; De Sanctis, V; Felisi, M; Galanello, R; Maggio, A; Masera, G; Piga, A; Schettini, F; Stefàno, I; Tricta, F, 2002) |
| "The sporadic occurrence of agranulocytosis in association with deferiprone and the highly variable frequency of other possible side effects such as arthralgia have created uncertainty about the true incidence of deferiprone-related complications." | 2.69 | A multi-center safety trial of the oral iron chelator deferiprone. ( Cohen, A; Galanello, R; Piga, A; Tricta, F; Vullo, C, 1998) |
| " Dose-response studies showed that incubating thalassemic RBC for 2 hours with L1 concentrations ranging from 0." | 2.68 | Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. ( Abrahamov, A; Goldfarb, A; Grinberg, L; Hebbel, RP; Olivieri, NF; Rachmilewitz, EA; Repka, T; Shalev, O, 1995) |
| " Adverse effects of DFP were nausea and vomiting (30%), significant arthropathy requiring stopping of the drug (30%), and reversible neutropenia in one patient." | 2.68 | Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia. ( Adhikari, D; Basu, AK; Bhattacharya, B; Biswas, A; Chakraborty, ML; Chandra, S; Maitra, TK; Roy, TB, 1995) |
| "Deferiprone was more efficacious than DFO in improving cardiac ejection fraction [MD 2." | 2.50 | A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. ( Kuo, KH; Mrkobrada, M, 2014) |
| "Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints." | 2.44 | Chelation therapy for iron overload. ( Barton, JC, 2007) |
| "Deferiprone has additive, or possibly synergistic, effects on iron excretion when combined with deferoxamine." | 2.40 | Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. ( Barman Balfour, JA; Foster, RH, 1999) |
| "Deferasirox was the most administered drug with doses between 500 mg/day-1,500 mg/day while deferiprone was ranged between 1,500 and 4,500 mg/day." | 1.62 | Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya. ( Bintoro, SUY; Qatrunnada, H; Wahyuni, S, 2021) |
| "Management of beta-thalassemia major (TM) requires life-long hemotransfusions leading to iron overload." | 1.56 | Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities. ( Georgiev, PG; Goranov, SE; Goranova-Marinova, VS; Sapunarova, KG, 2020) |
| "Brain iron overload is chronic and slow progressing and plays an important role in the pathogenesis of neurodegenerative disorders." | 1.51 | MRI imaging and histopathological study of brain iron overload of β-thalassemic mice. ( Fucharoen, S; Huaijantug, S; Morales, NP; Svasti, S; Teerapan, W; Yatmark, P, 2019) |
| "We concluded that pregnancy is not a contraindication in beta-thalassemia major; complex individual care is needed to achieve a safe outcome for the mother." | 1.51 | A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy. ( Abu, MA; Ahmad, MF; Arsad, N; Chew, KT; Omar, MH; Shafiee, MN; Zakaria, NZ, 2019) |
| "Deferiprone was the most effective chelator to improve glucose homeostasis in chronically transfused thalassemics." | 1.48 | Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major. ( Bagmar, S; Dabas, A; Gomber, S; Madhu, SV, 2018) |
| "Deferasirox monotherapy was less effective than deferiprone in improving myocardial siderosis and biventricular function and less effective than desferrioxamine in improving the LVEF." | 1.48 | MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. ( Allò, M; Cuccia, L; D'Ascola, DG; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Pepe, A; Pistoia, L; Positano, V; Restaino, G; Ricchi, P; Righi, R; Rosso, R; Spasiano, A, 2018) |
| "Diabetes mellitus is a common endocrinopathy in patients with β-thalassaemia major (β-TM), which is high prevalent in southern China." | 1.46 | Prevalence of diabetes mellitus in Chinese children with thalassaemia major. ( Bajoria, R; Chatterjee, R; Jiang, Y; Lai, Y; Liang, Y; Pan, H; Su, H; Xia, N, 2017) |
| "Deferasirox is an oral chelator." | 1.46 | Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017) |
| " The combination of drugs was well tolerated and no new adverse effects were observed." | 1.46 | Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India. ( Chandra, J; Dhingra, B; Jain, R; Mahto, D; Parakh, N; Sharma, S, 2017) |
| "In our study, chelation treatment during pregnancy did not prevent the delivery of healthy children." | 1.43 | Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? ( Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E, 2016) |
| "Patients with thalassemia major become transfusion- dependent with subsequent iron overload." | 1.42 | Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. ( Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA, 2015) |
| "Pulmonary iron overload was induced in heterozygous β-globin knockout mice (muβth-3/+, BKO)." | 1.42 | Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice. ( Chaisri, U; Fucharoen, S; Hemstapat, W; Morales, NP; Srichairatanakool, S; Svasti, S; Wichaiyo, S; Yatmark, P, 2015) |
| "Treatment of β-thalassemia major (β-TM) includes regular blood transfusions and iron chelation with subcutaneous injection of deferoxamine (DFO)." | 1.40 | Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients. ( Economou, M; Hatzipantelis, ES; Karasmanis, K; Perifanis, V; Tziomalos, K; Vlachaki, E, 2014) |
| "Deferiprone (20·6%) was less commonly prescribed in patients with elevated alanine aminotransferase; while a deferoxamine + deferiprone combination (17·9%) was more commonly used in patients with serum ferritin >2500 ng/ml or CMR T2* <20 ms." | 1.39 | Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. ( Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G, 2013) |
| "Deferiprone, because of its lower molecular weight, might cross into heart mitochondria more efficiently, improving their activity and, thereby, myocardial cell function." | 1.39 | Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. ( Barone, R; Calvaruso, G; Campisi, S; Capra, M; Caruso, V; Casale, M; Ciancio, A; Cianciulli, P; Cuccia, L; D'Ascola, G; Filosa, A; Gagliardotto, F; Gerardi, C; Maggio, A; Pitrolo, L; Prossomariti, L; Rigano, P; Rizzo, M; Vitrano, A, 2013) |
| "Thirteen patients (35." | 1.39 | Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy. ( Chao, YH; Lin, CD; Lin, CY; Peng, CT; Tsai, MH; Wu, HP; Wu, KH, 2013) |
| "There are no data from patients with β-thalassemia major." | 1.39 | Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major. ( Balocco, M; Forni, GL; Frassoni, F; Musallam, KM; Musso, M; Piaggio, G; Podestà, M; Pozzi, S; Rosa, A, 2013) |
| "Deferoxamine has universally been the standard therapeutic option for iron chelation therapy; however, its usage is troublesome, leading to suboptimal patient compliance." | 1.39 | Iron-chelation therapy with oral chelators in patients with thalassemia major. ( Kurtoglu, E; Uygun, V, 2013) |
| "Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron." | 1.37 | Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. ( Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G, 2011) |
| "Deferiprone has been shown to be capable of reducing the iron burden in patients with β-thalassaemia." | 1.37 | Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status. ( Chantharaksri, U; Fucharoen, S; Jirasomprasert, T; Jittangprasert, P; Limenta, LM; Morales, NP; Wilairat, P; Yamanont, P, 2011) |
| "Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy." | 1.37 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011) |
| "For chronic conditions such as thalassemia major, even when oral chelation therapy is available, support by an integrated team including a clinical psychologist and nurse specialist working with the treatment center is recommended to achieve optimal results." | 1.37 | Challenges of adherence and persistence with iron chelation therapy. ( El-Beshlawy, A; Evangeli, M; Porter, JB, 2011) |
| "Beta-thalassemia major (beta-TM), patients, asymptomatic and with preserved left ventricular ejection fraction (LVEF) were studied echocardiographically." | 1.36 | Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients. ( Farmaki, K; Fragatou, S; Kremastinos, D; Kyrzopoulos, S; Paraskevaidis, I; Tsiapras, D; Voudris, V, 2010) |
| "The risk of cardiac death during 1990-1999 and 2000-2008 was compared." | 1.36 | Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. ( Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K, 2010) |
| "Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major." | 1.36 | Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. ( Bina, P; Carta, MP; Cianciulli, P; Farci, P; Galanello, R; Grady, RW; Lai, ME; Maggio, A; Pepe, A; Sau, F; Vacquer, S, 2010) |
| "Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications." | 1.36 | Combined iron chelation therapy. ( Agus, A; Campus, S; Danjou, F; Galanello, R; Giardina, PJ; Grady, RW, 2010) |
| "Deferiprone was given at subsidized rates at a dose of 75/mg/day for seven days." | 1.35 | Oral iron chelation therapy with deferiprone in patients with Thalassemia Major. ( Adil, S; Ghani, F; Khurshid, M; Sajid, R, 2009) |
| "Five thalassemia major (TM) patients who were undergoing chelation monotherapy with DFO were enrolled." | 1.35 | Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia. ( Aessopos, A; Assimakopoulos, G; Polonofi, K; Rigaki, K; Tsironi, M, 2008) |
| "Deferiprone (L1) was discontinued as it was suspected to be the offending agent and prompt broad-spectrum antibiotic therapy was initiated after which the patient improved." | 1.34 | Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient. ( Inati, A; Koussa, S; Sheikh-Taha, M; Taher, A, 2007) |
| "In patients with thalassemia major (TM) who are non-compliant with long-term desferrioxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional hemosiderosis." | 1.33 | Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. ( Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Meletis, J; Tsironi, M, 2005) |
| "Deferiprone at a dose of 75 mg/kg/day is not sufficiently effective to maintain iron stores at a level which has been considered safe in all patients with iron overload." | 1.33 | Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. ( Dhillon, AP; Ellis, G; Hoffbrand, AV; Inati, A; Koussa, S; Sharara, A; Sheikh-Taha, M; Taher, A, 2005) |
| "Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients." | 1.33 | Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. ( Borgna-Pignatti, C; Cappellini, MD; Cnaan, A; De Stefano, P; Del Vecchio, GC; Forni, GL; Gamberini, MR; Ghilardi, R; Piga, A; Romeo, MA; Zhao, H, 2006) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 1.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "Comprehensive care for thalassemia major (TM) patients has achieved great advances in the world, yet psychosocial developmental aspects of care in families with afflicted members has made only limited progress." | 1.33 | Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY; Wu, KH, 2006) |
| "The parents of 18 thalassemia major patients (under 12 years of age) were interviewed (in two sessions) to determine their feelings, sources of stress, and support during their childrens' disease process." | 1.33 | Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY, 2006) |
| "With regard to bone resorption and remodeling markers, the urinary excretion of pyridinium crosslinks was higher in patients with thalassemia for HP fraction (p < 0." | 1.33 | Chelation therapy and bone metabolism markers in thalassemia major. ( De Sanctis, V; Fornasari, PM; Fortini, M; Gamberini, MR; Marconi, S; Pratelli, L; Verri, E; Zolezzi, C, 2006) |
| "Post transfusionnal iron overload is related to both a degree of RBC units transfused and excess intestinal absorption of Fe related to dyserythopoiesis." | 1.33 | [Post transfusionnal iron overload]. ( Rose, C, 2006) |
| "One group consisted of thalassemia major cases on deferiprone (L1) and the second group were those receiving desferrioxamine therapy." | 1.32 | Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators. ( Badakere, S; Ghosh, K; Pradhan, V, 2003) |
| "Deferiprone is an iron chelator that has the potential to be more effective than deferoxamine in removing intracellular iron from the heart." | 1.32 | Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. ( Fogliacco, E; Gaglioti, C; Piga, A; Tricta, F, 2003) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "A male thalassemia major patient who developed bone and cartilage abnormalities with a standard dose of desferrioxamine (DFX) given subcutaneously from the age of 4 years was treated with the oral iron chelator deferiprone (L1)." | 1.31 | Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine. ( Campisi, S; De Sanctis, V; Di Silvestro, G; Mangiagli, A; Urso, L, 2000) |
| "We analyzed 19 patients with thalassemia major who were undergoing long-term therapy with deferiprone (75 mg/kg/day every 8 hours)." | 1.30 | An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major. ( Atanackovic, G; Diav-Citrin, O; Koren, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 45 (16.30) | 18.2507 |
| 2000's | 110 (39.86) | 29.6817 |
| 2010's | 106 (38.41) | 24.3611 |
| 2020's | 15 (5.43) | 2.80 |
| Authors | Studies |
|---|---|
| Morales, NP | 8 |
| Rodrat, S | 2 |
| Piromkraipak, P | 1 |
| Yamanont, P | 4 |
| Paiboonsukwong, K | 1 |
| Fucharoen, S | 11 |
| Saleem, A | 1 |
| Waqar, E | 1 |
| Shuja, SH | 1 |
| Naeem, U | 1 |
| Moeed, A | 1 |
| Rais, H | 1 |
| Ahmed, J | 1 |
| Kwiatkowski, JL | 2 |
| Dillon, H | 1 |
| Baker, Z | 1 |
| Pena, A | 1 |
| Wang, Y | 2 |
| Syed, H | 1 |
| Sparks, S | 1 |
| Hamdy, M | 1 |
| El-Beshlawy, A | 5 |
| Veríssimo, MPA | 1 |
| Kanter, J | 1 |
| Inusa, B | 1 |
| Williams, S | 1 |
| Lee, D | 1 |
| Temin, NT | 1 |
| Fradette, C | 1 |
| Tricta, F | 12 |
| Ebeid, FSE | 1 |
| Elalfy, MS | 5 |
| Fragodimitri, C | 1 |
| Schiza, V | 1 |
| Giakoumis, A | 1 |
| Drakaki, K | 1 |
| Salichou, A | 1 |
| Karampatsos, F | 1 |
| Yousef, J | 1 |
| Karageorga, M | 1 |
| Berdoukas, V | 6 |
| Aessopos, A | 7 |
| Pepe, A | 8 |
| Meloni, A | 5 |
| Filosa, A | 9 |
| Pistoia, L | 2 |
| Borsellino, Z | 2 |
| D'Ascola, DG | 5 |
| Lisi, R | 2 |
| Putti, MC | 6 |
| Allò, M | 2 |
| Gamberini, MR | 5 |
| Quarta, A | 2 |
| Fidone, C | 2 |
| Casini, T | 1 |
| Restaino, G | 2 |
| Midiri, M | 5 |
| Mangione, M | 2 |
| Positano, V | 5 |
| Casale, M | 3 |
| Maggio, A | 12 |
| Kattamis, A | 4 |
| Felisi, M | 3 |
| Reggiardo, G | 1 |
| Bejaoui, M | 1 |
| Sherief, L | 1 |
| Christou, S | 2 |
| Cosmi, C | 1 |
| Della Pasqua, O | 2 |
| Del Vecchio, GC | 4 |
| Cuccia, L | 7 |
| Hassab, H | 1 |
| Kreka, M | 1 |
| Origa, R | 4 |
| Spino, M | 4 |
| Telfer, P | 3 |
| Tempesta, B | 1 |
| Vitrano, A | 6 |
| Tsang, YC | 1 |
| Zaka, A | 1 |
| Bonifazi, D | 2 |
| Ceci, A | 4 |
| Dhawan, P | 1 |
| Kanojia, RK | 1 |
| Chandra, J | 4 |
| Kumar, A | 1 |
| Anand, R | 1 |
| Gupta, S | 1 |
| Daar, S | 3 |
| Al Khabori, M | 1 |
| Al Rahbi, S | 1 |
| Hassan, M | 1 |
| El Tigani, A | 1 |
| Pennell, DJ | 9 |
| DivakarJose, RR | 1 |
| Delhikumar, CG | 1 |
| Ram Kumar, G | 1 |
| Georgiev, PG | 1 |
| Sapunarova, KG | 1 |
| Goranova-Marinova, VS | 1 |
| Goranov, SE | 1 |
| Zardkhoni, SZ | 1 |
| Moghaddam, AG | 1 |
| Rad, F | 1 |
| Ghatee, MA | 1 |
| Omidifar, N | 1 |
| Ghaedi, M | 1 |
| Etemadfar, P | 1 |
| Vadolas, J | 1 |
| Ng, GZ | 1 |
| Kysenius, K | 1 |
| Crouch, PJ | 1 |
| Dames, S | 1 |
| Eisermann, M | 1 |
| Nualkaew, T | 1 |
| Vilcassim, S | 1 |
| Schaeper, U | 1 |
| Grigoriadis, G | 1 |
| Qatrunnada, H | 1 |
| Bintoro, SUY | 1 |
| Wahyuni, S | 1 |
| Kolnagou, A | 8 |
| Kontoghiorghe, CN | 1 |
| Kontoghiorghes, GJ | 10 |
| Mainou, M | 1 |
| Kotsiafti, A | 1 |
| Klonizakis, P | 1 |
| Soulountsi, V | 1 |
| Apostolou, C | 1 |
| Psarras, K | 1 |
| Vlachaki, E | 9 |
| Noureldine, MHA | 1 |
| Taher, AT | 4 |
| Haydar, AA | 1 |
| Berjawi, A | 1 |
| Khamashta, MA | 1 |
| Uthman, I | 1 |
| Liang, Y | 1 |
| Bajoria, R | 1 |
| Jiang, Y | 1 |
| Su, H | 1 |
| Pan, H | 1 |
| Xia, N | 1 |
| Chatterjee, R | 1 |
| Lai, Y | 1 |
| Botzenhardt, S | 1 |
| Wong, ICK | 1 |
| Neubert, A | 1 |
| Gomber, S | 1 |
| Dabas, A | 1 |
| Bagmar, S | 1 |
| Madhu, SV | 1 |
| Mirlohi, MS | 1 |
| Yaghooti, H | 1 |
| Shirali, S | 1 |
| Aminasnafi, A | 1 |
| Olapour, S | 1 |
| Ballas, SK | 1 |
| Zeidan, AM | 1 |
| Duong, VH | 1 |
| DeVeaux, M | 1 |
| Heeney, MM | 1 |
| Fortin, PM | 1 |
| Fisher, SA | 1 |
| Madgwick, KV | 1 |
| Trivella, M | 1 |
| Hopewell, S | 1 |
| Doree, C | 1 |
| Estcourt, LJ | 1 |
| Aggarwal, M | 1 |
| Mirgh, S | 1 |
| Totadri, S | 2 |
| Bansal, D | 3 |
| Trehan, A | 2 |
| Khadwal, A | 1 |
| Bhatia, A | 1 |
| Sodhi, KS | 1 |
| Bhatia, P | 2 |
| Jain, R | 2 |
| Das, R | 1 |
| Khandelwal, N | 2 |
| Mao, L | 1 |
| Liu, W | 1 |
| Ding, F | 1 |
| Zou, P | 1 |
| Wang, X | 1 |
| Zhao, Q | 1 |
| Rao, H | 1 |
| Picariello, S | 1 |
| Corvino, F | 1 |
| Cerasari, G | 1 |
| Scianguetta, S | 1 |
| Rossi, F | 1 |
| Persico, M | 1 |
| Perrotta, S | 2 |
| Rosso, R | 1 |
| Spasiano, A | 4 |
| Righi, R | 1 |
| Ricchi, P | 4 |
| Panachan, J | 1 |
| Chokchaichamnankit, D | 1 |
| Weeraphan, C | 1 |
| Srisomsap, C | 1 |
| Masaratana, P | 1 |
| Hatairaktham, S | 1 |
| Panichkul, N | 1 |
| Svasti, J | 1 |
| Kalpravidh, RW | 1 |
| Ghosh, K | 3 |
| Eghbali, A | 1 |
| Khalilpour, A | 1 |
| Taherahmadi, H | 1 |
| Bagheri, B | 1 |
| Olivieri, NF | 12 |
| Sabouhanian, A | 1 |
| Gallie, BL | 1 |
| Lin, CH | 1 |
| Chen, X | 1 |
| Wu, CC | 1 |
| Wu, KH | 10 |
| Song, TS | 1 |
| Weng, TF | 1 |
| Hsieh, YW | 1 |
| Peng, CT | 12 |
| Binding, A | 1 |
| Ward, R | 1 |
| Tomlinson, G | 1 |
| Kuo, KHM | 1 |
| Yatmark, P | 4 |
| Huaijantug, S | 1 |
| Teerapan, W | 1 |
| Svasti, S | 4 |
| Ahmad, MF | 1 |
| Zakaria, NZ | 1 |
| Arsad, N | 1 |
| Chew, KT | 1 |
| Abu, MA | 1 |
| Shafiee, MN | 1 |
| Omar, MH | 1 |
| Viprakasit, V | 1 |
| Nuchprayoon, I | 1 |
| Chuansumrit, A | 2 |
| Torcharus, K | 1 |
| Pongtanakul, B | 1 |
| Laothamatas, J | 1 |
| Srichairatanakool, S | 5 |
| Pooliam, J | 1 |
| Supajitkasem, S | 1 |
| Suriyaphol, P | 1 |
| Tanphaichitr, VS | 1 |
| Tuchinda, S | 1 |
| Mallat, NS | 1 |
| Beydoun, A | 1 |
| Musallam, KM | 4 |
| Koussa, S | 6 |
| Piga, A | 14 |
| Longo, F | 2 |
| Cappellini, MD | 6 |
| Forni, GL | 4 |
| Quarta, G | 1 |
| Chiavilli, F | 1 |
| Commendatore, F | 1 |
| Mulas, S | 1 |
| Caruso, V | 7 |
| Galanello, R | 19 |
| Rigano, P | 4 |
| Calvaruso, G | 3 |
| Barone, R | 1 |
| Capra, M | 6 |
| Gagliardotto, F | 3 |
| Pitrolo, L | 5 |
| Prossomariti, L | 8 |
| Gerardi, C | 5 |
| Campisi, S | 5 |
| Cianciulli, P | 9 |
| Rizzo, M | 4 |
| D'Ascola, G | 2 |
| Ciancio, A | 2 |
| Porter, JB | 5 |
| Wood, J | 2 |
| Olivieri, N | 2 |
| Vichinsky, EP | 1 |
| Taher, A | 7 |
| Neufeld, E | 1 |
| Giardina, P | 1 |
| Thompson, A | 1 |
| Moore, B | 1 |
| Evans, P | 2 |
| Kim, HY | 1 |
| Macklin, EA | 1 |
| Trachtenberg, F | 1 |
| Bentley, A | 2 |
| Gillard, S | 1 |
| Connelly, J | 1 |
| Chao, YH | 1 |
| Lin, CY | 1 |
| Tsai, MH | 1 |
| Wu, HP | 1 |
| Lin, CD | 1 |
| Danjou, F | 3 |
| Cossa, S | 1 |
| Matta, G | 2 |
| Bina, P | 4 |
| Dessì, C | 6 |
| Defraia, E | 3 |
| Foschini, ML | 2 |
| Leoni, G | 4 |
| Morittu, M | 2 |
| Dadheech, S | 1 |
| Rao, AV | 1 |
| Shaheen, U | 1 |
| Hussien, MD | 1 |
| Jain, S | 1 |
| Jyothy, A | 1 |
| Munshi, A | 1 |
| El-Beshlawy, AM | 1 |
| El-Alfy, MS | 1 |
| Sari, TT | 2 |
| Chan, LL | 1 |
| Hatzipantelis, ES | 2 |
| Karasmanis, K | 1 |
| Perifanis, V | 9 |
| Tziomalos, K | 2 |
| Economou, M | 6 |
| Theodoridou, S | 1 |
| Vyzantiadis, TA | 1 |
| Teli, A | 3 |
| Neokleous, N | 3 |
| Kargioti, A | 1 |
| Vakalopoulou, S | 1 |
| Garypidou, V | 1 |
| Gombakis, N | 1 |
| Papachristou, F | 2 |
| Chaisri, U | 3 |
| Wichaiyo, S | 3 |
| Hemstapat, W | 3 |
| Dee, CM | 1 |
| Cheuk, DK | 3 |
| Ha, SY | 4 |
| Chiang, AK | 3 |
| Chan, GC | 4 |
| Kuo, KH | 1 |
| Mrkobrada, M | 1 |
| Sharma, R | 3 |
| Seth, A | 1 |
| Gohain, S | 1 |
| Kapoor, S | 1 |
| Singh, P | 1 |
| Pemde, H | 1 |
| Songdej, D | 1 |
| Sirachainan, N | 1 |
| Wongwerawattanakoon, P | 1 |
| Sasanakul, W | 1 |
| Kadegasem, P | 1 |
| Sungkarat, W | 1 |
| Schmidt, PJ | 1 |
| Racie, T | 1 |
| Westerman, M | 1 |
| Fitzgerald, K | 1 |
| Butler, JS | 1 |
| Fleming, MD | 1 |
| Ozturk, Z | 2 |
| Genc, GE | 2 |
| Kupesiz, A | 2 |
| Kurtoglu, E | 3 |
| Gumuslu, S | 2 |
| Adly, AM | 1 |
| Wali, Y | 2 |
| Tony, S | 2 |
| Samir, A | 1 |
| Elhenawy, YI | 1 |
| Di Maggio, R | 2 |
| Lai, E | 1 |
| Colletta, G | 1 |
| Quota, A | 2 |
| Rigoli, LC | 1 |
| Sacco, M | 2 |
| Attri, SV | 1 |
| Marwaha, RK | 2 |
| Moi, P | 1 |
| Follesa, I | 1 |
| Zappu, A | 1 |
| Cunico, A | 1 |
| Civolani, A | 1 |
| Podda, RA | 1 |
| Parakh, N | 2 |
| Prakash, O | 1 |
| Mahto, D | 2 |
| Dhingra, B | 2 |
| Sharma, S | 2 |
| Crisponi, G | 1 |
| Nurchi, VM | 1 |
| Crespo-Alonso, M | 1 |
| Sanna, G | 1 |
| Zoroddu, MA | 1 |
| Alberti, G | 1 |
| Biesuz, R | 1 |
| Hagag, AA | 2 |
| Hamam, MA | 1 |
| Taha, OA | 1 |
| Hazaa, SM | 1 |
| Elfaragy, MS | 1 |
| Elrifaey, SM | 1 |
| Abd El-Lateef, AE | 1 |
| Casu, C | 1 |
| Aghajan, M | 1 |
| Oikonomidou, PR | 1 |
| Guo, S | 1 |
| Monia, BP | 1 |
| Rivella, S | 1 |
| Saliba, AN | 1 |
| El Rassi, F | 1 |
| Osma, U | 1 |
| Eyigor, H | 1 |
| Yilmaz, MD | 1 |
| Aygener, N | 1 |
| Bellanti, F | 1 |
| Di Iorio, VL | 1 |
| Danhof, M | 1 |
| Diamantidis, MD | 1 |
| Agapidou, A | 2 |
| Vetsiou, E | 2 |
| Manafas, A | 1 |
| Fotiou, P | 1 |
| Poggi, M | 1 |
| Sorrentino, F | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| Lin, HJ | 1 |
| Kou, HS | 1 |
| Chiou, SS | 2 |
| Wu, SM | 1 |
| Karimi, M | 1 |
| Avazpour, A | 1 |
| Haghpanah, S | 2 |
| Toosi, F | 1 |
| Badie, A | 1 |
| Rossi, G | 3 |
| Frizziero, L | 1 |
| Hanif, A | 1 |
| Kidson-Gerber, G | 1 |
| Lindeman, R | 1 |
| Goel, H | 1 |
| Girisha, KM | 1 |
| Phadke, SR | 1 |
| Tselios, K | 1 |
| Tsatra, I | 7 |
| Tsayas, I | 1 |
| Modell, B | 1 |
| Khan, M | 1 |
| Darlison, M | 1 |
| Westwood, MA | 5 |
| Ingram, D | 1 |
| Beau-Salinas, F | 1 |
| Guitteny, MA | 1 |
| Donadieu, J | 1 |
| Jonville-Bera, AP | 1 |
| Autret-Leca, E | 1 |
| Al Zir, K | 1 |
| Habr, D | 1 |
| Kriemler-Krahn, U | 1 |
| Hmissi, A | 1 |
| Al Jefri, A | 1 |
| Jirasomprasert, T | 2 |
| Limenta, LM | 2 |
| Sirijaroonwong, S | 1 |
| Wilairat, P | 2 |
| Chantharaksri, U | 2 |
| Mehdizadeh, M | 1 |
| Nowroozzadeh, MH | 1 |
| Sajid, R | 1 |
| Ghani, F | 1 |
| Adil, S | 1 |
| Khurshid, M | 1 |
| Chouliaras, G | 3 |
| Moraitis, P | 2 |
| Zannikos, K | 2 |
| Berdoussi, E | 2 |
| Ladis, V | 5 |
| Zareifar, S | 1 |
| Jabbari, A | 1 |
| Cohan, N | 1 |
| Zanninelli, G | 2 |
| Breuer, W | 3 |
| Cabantchik, ZI | 4 |
| Tewari, S | 2 |
| Sharma, RK | 1 |
| Abrol, P | 1 |
| Sen, R | 1 |
| Malcovati, L | 1 |
| Moosavi-Movahedi, AA | 1 |
| Mousavy, SJ | 1 |
| Divsalar, A | 1 |
| Babaahmadi, A | 1 |
| Karimian, K | 1 |
| Shafiee, A | 1 |
| Kamarie, M | 1 |
| Poursasan, N | 1 |
| Farzami, B | 1 |
| Riazi, GH | 1 |
| Hakimelahi, GH | 1 |
| Tsai, FY | 1 |
| Ahmad, F | 1 |
| Amani, M | 1 |
| Saboury, AA | 1 |
| Chang, JS | 3 |
| Wang, LY | 2 |
| Hsiao, CC | 2 |
| Wang, SC | 1 |
| Hung, GY | 1 |
| Mok, AS | 2 |
| Chu, WC | 2 |
| Raskalkar, DD | 1 |
| Ho, MH | 2 |
| Telfer, PT | 1 |
| Warburton, F | 1 |
| Hadjigavriel, M | 1 |
| Sitarou, M | 1 |
| Angastiniotis, M | 1 |
| Fernandes, JL | 1 |
| Fabron, A | 1 |
| Verissimo, M | 1 |
| Campus, S | 2 |
| Farmaki, K | 4 |
| Tzoumari, I | 1 |
| Pappa, C | 1 |
| Prus, E | 2 |
| Fibach, E | 2 |
| Drakonaki, EE | 1 |
| Maris, TG | 1 |
| Maragaki, S | 1 |
| Klironomos, V | 1 |
| Papadakis, A | 1 |
| Karantanas, AH | 1 |
| Printza, N | 1 |
| Tzimouli, V | 3 |
| Athanassiou-Metaxa, M | 9 |
| Saewong, T | 1 |
| Ounjaijean, S | 1 |
| Mundee, Y | 1 |
| Pattanapanyasat, K | 1 |
| Ammirabile, M | 2 |
| Costantini, S | 2 |
| Cinque, P | 2 |
| Di Matola, T | 2 |
| Pagano, L | 2 |
| Balocco, M | 2 |
| Carrara, P | 1 |
| Pinto, V | 1 |
| Tsiapras, D | 1 |
| Fragatou, S | 1 |
| Kyrzopoulos, S | 1 |
| Paraskevaidis, I | 1 |
| Voudris, V | 1 |
| Kremastinos, D | 1 |
| Kattamis, C | 2 |
| Lai, ME | 1 |
| Grady, RW | 4 |
| Vacquer, S | 1 |
| Carta, MP | 1 |
| Sau, F | 1 |
| Farci, P | 1 |
| Agus, A | 4 |
| Giardina, PJ | 2 |
| Malaventura, C | 1 |
| Lippi, A | 1 |
| Romeo, MA | 4 |
| Bisconte, MG | 1 |
| Missere, M | 2 |
| Lombardi, M | 3 |
| El Alfy, M | 1 |
| Lee, CL | 1 |
| Lanza, AG | 1 |
| Di Costanzo, G | 1 |
| Jittangprasert, P | 1 |
| Venkateshwaran, S | 1 |
| Abdin, IA | 1 |
| El Safy, UR | 1 |
| Ibrahim, AS | 1 |
| Ebeid, FS | 1 |
| Salem, DS | 1 |
| Akrawinthawong, K | 1 |
| Chaowalit, N | 1 |
| Chatuparisuth, T | 1 |
| Siritanaratkul, N | 1 |
| Kleanthous, M | 2 |
| Rasalkar, DD | 1 |
| Pantalone, GR | 2 |
| Magnano, C | 2 |
| Argento, C | 1 |
| Violi, P | 1 |
| Malizia, R | 3 |
| D'Amico, G | 1 |
| Morabito, A | 2 |
| Gluud, C | 2 |
| Voskaridou, E | 2 |
| Christoulas, D | 1 |
| Terpos, E | 2 |
| Luangasanatip, N | 1 |
| Chaiyakunapruk, N | 1 |
| Upakdee, N | 1 |
| Wong, P | 1 |
| Smith, GC | 5 |
| Alpendurada, F | 2 |
| Carpenter, JP | 2 |
| Alam, MH | 1 |
| Karagiorga, M | 2 |
| Gotsis, ED | 2 |
| Tanner, MA | 5 |
| Roughton, M | 2 |
| Aloj, G | 1 |
| Iacono, A | 1 |
| Bonifazi, F | 1 |
| Cassarà, F | 1 |
| Harmatz, P | 1 |
| Evangeli, M | 1 |
| Aydinok, Y | 4 |
| Manz, CY | 1 |
| Nair, SV | 3 |
| Banya, W | 1 |
| Walker, JM | 4 |
| Karakukcu, C | 1 |
| Karakukcu, M | 1 |
| Unal, E | 1 |
| Patiroglu, T | 1 |
| Ozdemir, MA | 1 |
| Torun, YA | 1 |
| Tang, PH | 1 |
| Cassinerio, E | 1 |
| Roghi, A | 1 |
| Pedrotti, P | 1 |
| Brevi, F | 1 |
| Zanaboni, L | 1 |
| Graziadei, G | 1 |
| Pattoneri, P | 1 |
| Milazzo, A | 1 |
| Lucania, G | 1 |
| Mirbehbahani, N | 1 |
| Jahazi, A | 1 |
| Rahim Abad, HH | 1 |
| Tankanitlert, J | 1 |
| Chantraraksri, U | 1 |
| Efthimia, V | 1 |
| Natsiopoulos, K | 1 |
| Ioannou, A | 1 |
| Erdoğan, E | 1 |
| Canatan, D | 1 |
| Ormeci, AR | 1 |
| Vural, H | 1 |
| Aylak, F | 1 |
| Ruivard, M | 1 |
| Podestà, M | 1 |
| Musso, M | 1 |
| Piaggio, G | 1 |
| Pozzi, S | 1 |
| Rosa, A | 1 |
| Frassoni, F | 1 |
| Uygun, V | 1 |
| D'Ascola, GD | 1 |
| Santodirocco, M | 1 |
| Peluso, A | 1 |
| Gulino, L | 1 |
| Zachariah, M | 1 |
| Bashir, W | 1 |
| Al Rawas, A | 1 |
| Pathare, A | 1 |
| Wanless, IR | 1 |
| Sweeney, G | 1 |
| Dhillon, AP | 2 |
| Guido, M | 1 |
| Schwartz, E | 1 |
| Cohen, AR | 4 |
| Richardson, DR | 1 |
| Anderson, LJ | 2 |
| Wonke, B | 9 |
| Prescott, E | 2 |
| Holden, S | 1 |
| Schettini, F | 4 |
| Piacente, L | 1 |
| De Santis, A | 1 |
| Giordano, P | 1 |
| De Mattia, D | 1 |
| Pradhan, V | 1 |
| Badakere, S | 1 |
| St Pierre, TG | 1 |
| Fischer, R | 4 |
| Engelhardt, R | 2 |
| Brittenham, GM | 4 |
| Nathan, DG | 3 |
| Pippard, MJ | 2 |
| Weatherall, DJ | 3 |
| Mourad, FH | 1 |
| Hoffbrand, AV | 10 |
| Sheikh-Taha, M | 5 |
| Khoriaty, AI | 1 |
| Westwood, M | 1 |
| Gaglioti, C | 1 |
| Fogliacco, E | 1 |
| Chow, KC | 1 |
| Chen, JH | 1 |
| Chiang, YP | 1 |
| Lin, TY | 1 |
| Tsai, CH | 4 |
| De Sanctis, V | 4 |
| Galia, M | 1 |
| Bartolotta, V | 1 |
| Mangiagli, A | 2 |
| Nielsen, P | 2 |
| Hider, RC | 1 |
| Pootrakul, P | 2 |
| Sirankapracha, P | 2 |
| Sankote, J | 1 |
| Kachintorn, U | 1 |
| Maungsub, W | 1 |
| Sriphen, K | 1 |
| Thakernpol, K | 1 |
| Atisuk, K | 1 |
| Chantraluksri, U | 1 |
| Shalev, O | 3 |
| Marshall, R | 1 |
| Kirkland, D | 1 |
| Minto, S | 1 |
| Taparkou, A | 2 |
| Tourkantoni, N | 2 |
| Kanakoudi-Tsakalidou, F | 2 |
| Kassou, C | 1 |
| Berdousi, H | 1 |
| Papassotiriou, I | 3 |
| Viens, AM | 1 |
| Savulescu, J | 1 |
| Kousi, A | 1 |
| Ikonomou, M | 1 |
| Tsantali, H | 1 |
| Sametband, M | 1 |
| Hershko, C | 2 |
| Kellenberger, CJ | 1 |
| Schmugge, M | 1 |
| Saurenmann, T | 1 |
| Di Gennaro, L | 1 |
| Eber, SW | 1 |
| Willi, UV | 1 |
| Babyn, PS | 1 |
| Alymara, V | 1 |
| Bourantas, D | 1 |
| Chaidos, A | 1 |
| Bouranta, P | 1 |
| Gouva, M | 1 |
| Vassou, A | 1 |
| Tzouvara, E | 1 |
| Bourantas, KL | 1 |
| Tsironi, M | 4 |
| Deftereos, S | 3 |
| Andriopoulos, P | 2 |
| Farmakis, D | 3 |
| Meletis, J | 2 |
| Hershko, CM | 1 |
| Link, GM | 1 |
| Konijn, AM | 1 |
| Bartakke, S | 1 |
| Bavdekar, SB | 1 |
| Kondurkar, P | 1 |
| Muranjan, MN | 1 |
| Manglani, MV | 1 |
| Douskou, M | 1 |
| Stamoulakatou, A | 1 |
| Ourailidis, A | 1 |
| Loukopoulos, D | 2 |
| Meo, A | 1 |
| Ruggeri, A | 1 |
| La Rosa, MA | 1 |
| Zanghì, L | 1 |
| Kordes, U | 1 |
| Polonifi, K | 1 |
| Moyssakis, I | 1 |
| Rund, D | 1 |
| Rachmilewitz, E | 1 |
| Crobu, G | 1 |
| Muroni, PP | 1 |
| Sharara, A | 1 |
| Inati, A | 3 |
| Ellis, G | 2 |
| Borgna-Pignatti, C | 1 |
| De Stefano, P | 1 |
| Ghilardi, R | 1 |
| Zhao, H | 1 |
| Cnaan, A | 1 |
| Martín, M | 1 |
| Estornell, J | 1 |
| Orero, M | 1 |
| Pérez, JL | 1 |
| Ridocci, F | 1 |
| Martínez, V | 1 |
| Pathare, AV | 1 |
| Cracolici, E | 1 |
| De Marchi, D | 1 |
| Platis, O | 1 |
| Anagnostopoulos, G | 2 |
| Posantzis, M | 1 |
| Gotsis, E | 2 |
| Tolis, G | 2 |
| Wu, SF | 3 |
| Liang, DC | 1 |
| Yang, CP | 1 |
| Jang, RC | 1 |
| Neufeld, EJ | 1 |
| Tavecchia, L | 1 |
| Masera, N | 1 |
| Russo, P | 1 |
| Cirò, A | 1 |
| Vincenzi, A | 1 |
| Vimercati, C | 1 |
| Masera, G | 2 |
| Huang, YC | 1 |
| Chang, JG | 1 |
| Ho, YJ | 1 |
| Wang, CH | 1 |
| Tsai, FJ | 1 |
| Chik, KW | 1 |
| Ling, SC | 1 |
| Lee, AC | 1 |
| Luk, CW | 1 |
| Lam, CW | 1 |
| Ng, IO | 1 |
| Kuo, HT | 2 |
| Tsai, MY | 2 |
| Angelopoulos, N | 1 |
| Rombopoulos, G | 1 |
| Christoforidis, A | 4 |
| Porcu, M | 1 |
| Landis, N | 1 |
| Salis, S | 1 |
| Corda, M | 1 |
| Orrù, P | 1 |
| Serra, E | 1 |
| Usai, B | 1 |
| Haritandi, A | 1 |
| Tsitourides, I | 1 |
| Karyda, S | 1 |
| Ioannidou-Papagiannaki, E | 1 |
| Haralambidou-Vranitsa, S | 1 |
| Klonizakis, I | 1 |
| Pratelli, L | 1 |
| Verri, E | 1 |
| Fortini, M | 1 |
| Marconi, S | 1 |
| Zolezzi, C | 1 |
| Fornasari, PM | 1 |
| Barton, JC | 1 |
| Assomull, R | 1 |
| Rose, C | 1 |
| Unal, S | 1 |
| Gücer, S | 1 |
| Kale, G | 1 |
| Besbas, N | 1 |
| Ozen, S | 1 |
| Gümrük, F | 1 |
| Zevgaridou, E | 1 |
| Apostolakou, F | 1 |
| Abdelrazik, N | 1 |
| Kati, M | 1 |
| Polonifi, E | 1 |
| Ulger, Z | 1 |
| Nart, D | 1 |
| Terzi, A | 1 |
| Cetiner, N | 1 |
| Zimmermann, A | 2 |
| Manz, C | 1 |
| Spanos, G | 1 |
| Assimakopoulos, G | 1 |
| Polonofi, K | 1 |
| Rigaki, K | 1 |
| Zafiriou, D | 1 |
| Pibiri, M | 1 |
| Angelucci, E | 1 |
| Barosi, G | 1 |
| Camaschella, C | 1 |
| Cazzola, M | 1 |
| Marchetti, M | 1 |
| Tura, S | 1 |
| al-Refaie, FN | 4 |
| Kosaryan, M | 1 |
| Tondury, P | 2 |
| Repka, T | 1 |
| Goldfarb, A | 1 |
| Grinberg, L | 1 |
| Abrahamov, A | 1 |
| Rachmilewitz, EA | 1 |
| Hebbel, RP | 2 |
| Matsui, D | 4 |
| Berkovitch, M | 5 |
| Blendis, LM | 1 |
| Cameron, RG | 2 |
| McClelland, RA | 3 |
| Liu, PP | 3 |
| Templeton, DM | 3 |
| Koren, G | 9 |
| Bartlett, AN | 1 |
| Sheppard, L | 1 |
| Barr, J | 1 |
| Nortey, P | 1 |
| Laxer, RM | 1 |
| Inman, R | 1 |
| Pritzker, KP | 1 |
| Fritzler, MJ | 1 |
| Hermann, C | 1 |
| Klein, J | 3 |
| Fassos, FF | 1 |
| Fernandes, D | 1 |
| Blendis, L | 1 |
| Cameron, R | 1 |
| Veys, PA | 1 |
| Wilkes, S | 1 |
| Marciani, MG | 1 |
| Iani, C | 1 |
| Desiato, MT | 1 |
| Spanedda, F | 1 |
| Bassetti, MA | 1 |
| Agarwal, MB | 2 |
| Adhikari, D | 1 |
| Roy, TB | 1 |
| Biswas, A | 1 |
| Chakraborty, ML | 1 |
| Bhattacharya, B | 1 |
| Maitra, TK | 1 |
| Basu, AK | 1 |
| Chandra, S | 1 |
| Castriota-Scanderbeg, A | 1 |
| Pope, E | 1 |
| Fassos, F | 1 |
| Shilalukey, K | 1 |
| Kaufman, M | 1 |
| Bradley, S | 1 |
| Francombe, WH | 1 |
| Amankwah, K | 1 |
| Goldberg, E | 1 |
| Shear, N | 1 |
| Loebstein, R | 1 |
| Dalal, I | 1 |
| Nisbet-Brown, E | 1 |
| Meydan, N | 1 |
| Andrews, D | 1 |
| Loubser, MD | 1 |
| Roifman, CM | 1 |
| AL-Refaie, F | 1 |
| Davis, B | 1 |
| Siritanakatkul, N | 1 |
| Jackson, BF | 1 |
| Cochrane, J | 1 |
| Hirt, A | 1 |
| Cohen, A | 1 |
| Vullo, C | 2 |
| McLaren, CE | 1 |
| Burt, AD | 1 |
| Fleming, KA | 1 |
| Kowdley, KV | 1 |
| Kaplan, MM | 1 |
| Wright, C | 1 |
| Phillips, RA | 1 |
| Hoey, J | 1 |
| Shuchman, M | 1 |
| Callea, F | 1 |
| Stella, M | 1 |
| Pinzello, G | 1 |
| Martin, MB | 1 |
| Diav-Citrin, O | 1 |
| Atanackovic, G | 1 |
| Lala, R | 1 |
| Chiabotto, P | 1 |
| Di Stefano, M | 1 |
| Isaia, GC | 1 |
| Garofalo, F | 1 |
| Sher, GD | 1 |
| Bartfay, WJ | 1 |
| Lehotay, DC | 1 |
| de Franceschi, L | 1 |
| Collell, M | 1 |
| Olivieri, O | 1 |
| Corrocher, R | 1 |
| Brugnara, C | 1 |
| Nisli, G | 2 |
| Kavakli, K | 2 |
| Coker, C | 1 |
| Kantar, M | 1 |
| Cetingül, N | 1 |
| Barman Balfour, JA | 1 |
| Foster, RH | 1 |
| Pati, HP | 1 |
| Choudhry, VP | 1 |
| Dipalma, A | 1 |
| Birmingham, K | 1 |
| Di Silvestro, G | 1 |
| Urso, L | 1 |
| Anderson, D | 1 |
| Yardley-Jones, A | 1 |
| Vives-Bauza, C | 1 |
| Chua-Anusorn, W | 1 |
| Cole, C | 1 |
| Webb, J | 1 |
| Lucas, GN | 1 |
| Perera, BJ | 1 |
| Fonseka, EA | 1 |
| De Silva, DD | 1 |
| Fernandopulle, M | 1 |
| Afanas'ev, IB | 1 |
| Afanas'ev, II | 1 |
| Deeva, IB | 1 |
| Korkina, LG | 1 |
| Korkina, L | 1 |
| De Luca, C | 1 |
| Deeva, I | 1 |
| Nobili, B | 1 |
| Passi, S | 1 |
| Puddu, P | 1 |
| Del Vecchio , GC | 1 |
| Crollo, E | 1 |
| De Mattia , D | 1 |
| Rajeshwari, K | 1 |
| Balveer, K | 1 |
| Pyar, K | 1 |
| Neeman, R | 1 |
| Mourad, F | 1 |
| Baiardi, P | 1 |
| Carnelli, V | 1 |
| Stefàno, I | 1 |
| Wickens, DG | 1 |
| Gupte, SS | 1 |
| Viswanathan, C | 1 |
| Vasandani, D | 1 |
| Ramanathan, J | 1 |
| Desai, N | 1 |
| Puniyani, RR | 1 |
| Chhablani, AT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies[NCT01825512] | Phase 3 | 435 participants (Actual) | Interventional | 2014-03-17 | Completed | ||
| A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload[NCT01511848] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2012-02-29 | Not yet recruiting | ||
| Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure: a Phase II.a Pharmacokinetics, Ease-of-swallow, Safety and Proof-of-concept Study Among Children 6-18 Years of Age[NCT06012266] | Phase 2 | 12 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia[NCT00529152] | Phase 3 | 100 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients[NCT00350662] | Phase 3 | 95 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| Prospective Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut University Children Hospital (AUCH)[NCT05303506] | 50 participants (Anticipated) | Observational | 2022-07-02 | Not yet recruiting | |||
| Acute Effect of a Single Dose of Oral Iron on Pancreatic Beta Cell Function in Healthy Individuals: a Quasi-experimental Single Arm Before-and-after (Pre-post) Study[NCT05238987] | 15 participants (Actual) | Interventional | 2020-10-10 | Completed | |||
| A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738] | Phase 1 | 6 participants (Actual) | Interventional | 2008-06-20 | Completed | ||
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance[NCT00103753] | Phase 4 | 65 participants | Interventional | 2004-05-31 | Active, not recruiting | ||
| Chelation Therapy of Iron Overload With Oral Pyridoxal Isonicotinoyl Hydrazone[NCT00000588] | Phase 2 | 120 participants (Actual) | Interventional | 1989-06-05 | Completed | ||
| Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients[NCT00349453] | Phase 2 | 24 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in cardiac iron concentration (measured using cardiac MRI T2*), assessed as difference between value at 12 months minus value at baseline. MRI T2* is a non-invasive method based on gradient echo (GRE) sequences, where T2* represents the spin-spin relaxation times, measured in milliseconds. The faster the curve decreases (ie, the smaller T2*), the greater amount of iron is in the tissue. Treatment success was assessed as follows: if baseline cardiac T2* was less than 20 ms, an increase of 10% or more after 1 year of treatment was defined as treatment success; if baseline cardiac T2* was more than 20 ms, any increase or a decrease of less than 10% after 1 year of treatment was defined as treatment success. (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | milliseconds (ms) (Mean) |
|---|---|
| Deferiprone | 0.488 |
| Deferasirox | 1.121 |
Change in serum ferritin level, assessed as difference between value at 12 months minus value at baseline. (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Deferiprone | -397.583 |
| Deferasirox | -398.184 |
Change in liver iron concentration (measured using liver MRI), assessed as difference between value at 12 months minus value at baseline. (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | mg/g (Mean) |
|---|---|
| Deferiprone | -0.848 |
| Deferasirox | -2.975 |
Percentage of successfully chelated patients is assessed by serum ferritin levels (in all patients) and cardiac MRI T2* (in patients above 10 years of age able to perform an MRI scan without sedation) (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferiprone | 69 |
| Deferasirox | 80 |
The change in serum ferritin concentration from baseline to week 24 was measured and analyzed for all participants in the study (NCT00529152)
Timeframe: Baseline and 24 weeks
| Intervention | ug/L (Mean) |
|---|---|
| Ferriprox Oral Solution | -355.5 |
Number of Adverse Events over 24 weeks (NCT00529152)
Timeframe: 24 Weeks
| Intervention | Adverse Events (Number) |
|---|---|
| Ferriprox Oral Solution | 212 |
20 reviews available for deferiprone and Anemia, Cooley's
| Article | Year |
|---|---|
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Ferritins; Hemoglobinopathies; Humans; | 2023 |
Clinical Challenges with Iron Chelation in Beta Thalassemia.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyr | 2023 |
Rheumatological complications of beta-thalassaemia: an overview.
Topics: Arthritis; beta-Thalassemia; Blood Transfusion; Connective Tissue Diseases; Deferiprone; Femur Head | 2018 |
The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Deferiprone; Deferoxamine; Humans; Iron Ch | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Defer | 2018 |
A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
Topics: beta-Thalassemia; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agent | 2014 |
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Mana | 2016 |
Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.
Topics: Adult; Arthritis; beta-Thalassemia; Deferiprone; Humans; Iron Chelating Agents; Knee Joint; Male; Py | 2008 |
Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Topics: beta-Thalassemia; Deferiprone; Disease Progression; DNA Methylation; Erythrocyte Transfusion; Erythr | 2009 |
Update on survival in thalassemia major.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Follow-Up Studies; Humans; Iron | 2009 |
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy | 2011 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Ir | 2013 |
LPI-labile plasma iron in iron overload.
Topics: beta-Thalassemia; Deferiprone; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidation-Reducti | 2005 |
Beta-thalassemia.
Topics: Antioxidants; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Hematopoietic Ste | 2005 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron | 2007 |
Oral iron-chelating therapy: the L1 experience.
Topics: Administration, Oral; Anemia; Animals; beta-Thalassemia; Chelation Therapy; Deferiprone; Humans; Iro | 1994 |
Long-term trials of deferiprone in Cooley's anemia.
Topics: beta-Thalassemia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron | 1998 |
Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Topics: beta-Thalassemia; Clinical Trials as Topic; Deferiprone; Humans; Iron; Iron Chelating Agents; Pyrido | 1999 |
Oral iron chelation therapy for thalassaemia: an uncertain scene.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron | 2000 |
76 trials available for deferiprone and Anemia, Cooley's
| Article | Year |
|---|---|
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron C | 2024 |
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Topics: Administration, Oral; Adolescent; Agranulocytosis; Albania; Anemia, Sickle Cell; beta-Thalassemia; C | 2020 |
Differentially expressed plasma proteins of β-thalassemia/hemoglobin E patients in response to curcuminoids/vitamin E antioxidant cocktails.
Topics: Acetylcysteine; Adult; beta-Thalassemia; Blood Proteins; Curcumin; Deferiprone; Drug Therapy, Combin | 2019 |
Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled study.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritin | 2019 |
Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Topics: Administration, Oral; Adult; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferasirox; De | 2019 |
Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Topics: Acute Disease; Administration, Oral; Adolescent; beta-Thalassemia; Child; Child, Preschool; Deferipr | 2013 |
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Heart Failure | 2013 |
Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
Topics: Administration, Oral; Adolescent; Alanine Transaminase; beta-Thalassemia; Child; Child, Preschool; C | 2015 |
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxa | 2015 |
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2015 |
Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
Topics: Administration, Oral; Antioxidants; beta-Thalassemia; Blood Chemical Analysis; Blood Transfusion; Ch | 2015 |
Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β-Thalassemia.
Topics: beta-Thalassemia; Child; Child, Preschool; Deferiprone; Humans; Infant; Infant, Newborn; Iron Chelat | 2016 |
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxa | 2009 |
Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; beta-Thalassemia; Blood Urea N | 2009 |
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxami | 2010 |
Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.
Topics: beta-Thalassemia; Bone Marrow; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combinati | 2010 |
Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Administrati | 2010 |
The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
Topics: Administration, Oral; Agranulocytosis; Anemia, Sickle Cell; beta-Thalassemia; Chemistry, Pharmaceuti | 2010 |
Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiovascular Abnormalities; Deferiprone; Echocardiography, Do | 2011 |
Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iro | 2011 |
Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferiprone; Defero | 2011 |
Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Administrati | 2011 |
Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
Topics: Adolescent; beta-Thalassemia; Blood Proteins; Blood Transfusion; Chelation Therapy; Child; Deferipro | 2012 |
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Comorbidity; Deferasirox; Deferiprone; Deferoxamine; Drug Therap | 2012 |
Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Comb | 2012 |
The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Drug Administration Routes; D | 2012 |
Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients.
Topics: Adolescent; Adult; Area Under Curve; beta-Thalassemia; Deferiprone; Female; Glucuronides; Hemoglobin | 2012 |
The effects of chelators on zinc levels in patients with thalassemia major.
Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Demography; Female; | 2013 |
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Biopsy; Blood Transfusion; Child; Deferiprone; Female; Humans; | 2002 |
Effects of deferiprone on immune status and cytokine pattern in thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; CD4-CD8 Ratio; Child; Cohort Studies; Cytokines; Deferiprone; H | 2002 |
Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Chelating Agents; Child; Deferiprone; Defero | 2003 |
Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Female; Fe | 2003 |
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Ch | 2003 |
Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.
Topics: Administration, Oral; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Heart Function Tests; Hum | 2003 |
Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand.
Topics: Administration, Oral; Adult; beta-Thalassemia; Deferiprone; Erythrocyte Membrane; Erythropoietin; Fe | 2003 |
Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
Topics: Adolescent; Adult; beta-Thalassemia; Cell Cycle; Chelation Therapy; Chromosome Aberrations; Cross-Ov | 2003 |
Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferiprone; Defe | 2003 |
Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Com | 2004 |
Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.
Topics: beta-Thalassemia; Biomarkers; Deferiprone; Erythrocyte Membrane; Follow-Up Studies; Hemoglobin E; Hu | 2004 |
Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response | 2004 |
Deferiprone as an oral iron chelator in sickle cell disease.
Topics: Administration, Oral; Adult; Aged; Anemia, Sickle Cell; beta-Thalassemia; Deferiprone; Drug Evaluati | 2005 |
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female; Humans; Iron; Iron Che | 2006 |
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Erythrocyte | 2006 |
Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Humans; Iron Overload; Magnetic Resonanc | 2006 |
Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Thera | 2004 |
Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan.
Topics: Adolescent; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, | 2006 |
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Topics: Administration, Oral; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Clinical Protocols; Com | 2006 |
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali | 2006 |
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined | 2006 |
Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug Thera | 2007 |
Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Female; Granulocyte Colony-St | 2007 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug Thera | 2007 |
A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Ir | 2007 |
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Topics: Administration, Oral; Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug The | 2008 |
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Deferiprone; Erythrocyte Membrane; Erythrocytes; Humans; Iron | 1995 |
Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Dr | 1995 |
Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Topics: Adult; Aged; Ascorbic Acid; beta-Thalassemia; Deferiprone; Feces; Female; Ferritins; Humans; Iron; I | 1995 |
Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Child; Cooperative Behavior; Deferiprone; | 1994 |
Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
Topics: Administration, Oral; beta-Thalassemia; Chelation Therapy; Deferiprone; Humans; Iron; Iron Chelating | 1993 |
Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one.
Topics: Administration, Oral; Adult; Agranulocytosis; beta-Thalassemia; Deferiprone; Female; Humans; Immunol | 1993 |
Subclinical auditory and visual involvement during oral deferiprone therapy.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Evoked Potentials, Au | 1996 |
Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Child, Preschool | 1995 |
Salivary measurement of deferiprone concentrations and correlation with serum levels.
Topics: beta-Thalassemia; Deferiprone; Female; Humans; Iron Chelating Agents; Male; Prospective Studies; Pyr | 1997 |
Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
Topics: Adolescent; Adult; Antibody Formation; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Defer | 1997 |
Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelating | 1998 |
A multi-center safety trial of the oral iron chelator deferiprone.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Ch | 1998 |
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Biopsy; Child; Deferiprone; Deferoxamine; Disease Progression; | 1998 |
Combined therapy with deferiprone and desferrioxamine.
Topics: Adolescent; Adult; Aged; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response Relationship, Dr | 1998 |
Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity.
Topics: Adolescent; Adult; beta-Thalassemia; Carrier Proteins; Child; Chlorides; Deferiprone; Erythrocyte Me | 1999 |
Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience.
Topics: Adolescent; beta-Thalassemia; Child; Deferiprone; Female; Humans; India; Iron Chelating Agents; Male | 1999 |
A trial of deferiprone in transfusion-dependent iron overloaded children.
Topics: Adolescent; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Ferritins; Humans; Iron Chelatin | 2000 |
Combined oral and parenteral iron chelation in beta thalassaemia major.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Drug Th | 2000 |
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; De | 2001 |
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.
Topics: Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Blood Transfusion; Child | 2002 |
Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating | 1992 |
180 other studies available for deferiprone and Anemia, Cooley's
| Article | Year |
|---|---|
Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients.
Topics: Adolescent; Adult; Antioxidants; beta-Thalassemia; Deferiprone; Erythrocytes; Female; Ferritins; Glu | 2022 |
Nephrolithiasis in two patients on iron chelation therapy: A case report.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Human | 2023 |
Successful chelation in beta-thalassemia major in the 21st century.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; | 2023 |
Prospective CMR Survey in Children With Thalassemia Major: Insights From a National Network.
Topics: Adolescent; Age Factors; beta-Thalassemia; Cardiomyopathies; Child; Deferiprone; Deferoxamine; Femal | 2020 |
Wrist Joint Skeletal Changes in Children With Transfusion-dependent Thalassemia.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferip | 2020 |
Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up.
Topics: Adolescent; beta-Thalassemia; Chelation Therapy; Cohort Studies; Deferasirox; Deferiprone; Female; F | 2020 |
Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Ov | 2021 |
Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritin | 2020 |
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; | 2021 |
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Topics: Acetylgalactosamine; Animals; beta-Thalassemia; Deferiprone; Disease Models, Animal; Drug Therapy, C | 2021 |
Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya.
Topics: Adult; Benzoates; beta-Thalassemia; Costs and Cost Analysis; Deferasirox; Deferiprone; Drug Utilizat | 2021 |
Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; He | 2017 |
A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone.
Topics: Adult; Agranulocytosis; beta-Thalassemia; Bone Marrow Cells; Bone Marrow Examination; Chelation Ther | 2016 |
Prevalence of diabetes mellitus in Chinese children with thalassaemia major.
Topics: Alanine Transaminase; beta-Thalassemia; Blood Glucose; Child; China; Deferiprone; Diabetes Mellitus; | 2017 |
Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study.
Topics: Age Factors; beta-Thalassemia; Child; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Med | 2018 |
Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major.
Topics: Adolescent; beta-Thalassemia; Blood Glucose; Chelation Therapy; Child; Child, Preschool; Deferiprone | 2018 |
Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Blood Transfusion; Chelation Therapy; Combined Moda | 2018 |
Hepatic and Cardiac Iron Overload - Revising the Role of Deferiprone.
Topics: beta-Thalassemia; Deferiprone; Heart; Humans; Iron Chelating Agents; Iron Overload; Pyridones | 2018 |
Hepatic and Cardiac Iron-load in Children on Long-term Chelation with Deferiprone for Thalassemia Major.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Child; Cross-Sectional Studies; Deferiprone; Drug A | 2018 |
A ratiometric fluorometric and colorimetric probe for the β-thalassemia drug deferiprone based on the use of gold nanoclusters and carbon dots.
Topics: beta-Thalassemia; Carbon; Colorimetry; Deferiprone; Fluorometry; Gold; Humans; Iron; Metal Nanoparti | 2018 |
Life-Threatening Drug-Induced Liver Injury in a Patient with β-Thalassemia Major and Severe Iron Overload on Polypharmacy.
Topics: Adrenergic beta-Antagonists; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver In | 2018 |
MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Substitution | 2018 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
Topics: Administration, Oral; Anemia, Diamond-Blackfan; beta-Thalassemia; Blood Transfusion; Deferasirox; De | 2019 |
Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Biomarkers; Deferiprone; Humans; Iron; Iro | 2019 |
MRI imaging and histopathological study of brain iron overload of β-thalassemic mice.
Topics: Animals; beta-Thalassemia; Brain; Chelating Agents; Computer Graphics; Deferiprone; Disease Models, | 2019 |
A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy.
Topics: beta-Globins; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Deferiprone; Female; Homozygote | 2019 |
Deferiprone-induced seizures in a patient with β-thalassemia major.
Topics: Adult; beta-Thalassemia; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; | 2013 |
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; | 2013 |
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Heart Diseases; Humans; Iron Chelating A | 2013 |
Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
Topics: beta-Thalassemia; Cost-Benefit Analysis; Deferiprone; Drug Costs; Health Care Costs; Humans; Iron Ch | 2013 |
Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
Topics: Acoustic Impedance Tests; Adolescent; Adult; Audiometry, Pure-Tone; beta-Thalassemia; Blood Transfus | 2013 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Defer | 2013 |
Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.
Topics: Adolescent; Alanine; Amino Acid Substitution; Arginine; beta-Thalassemia; Child; Child, Preschool; D | 2013 |
Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.
Topics: beta-Thalassemia; Child; Child, Preschool; Deferiprone; Female; Humans; Iron Chelating Agents; Leuko | 2014 |
Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Chi-Square Distribution; Child; Deferiprone; | 2014 |
Laboratory investigation of platelet function in patients with thalassaemia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Platelets; Child; Deferasirox; Deferiprone; De | 2014 |
Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
Topics: Animals; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Disease Models, Animal; Female; | 2014 |
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; | 2014 |
Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy.
Topics: Adolescent; Adolescent Development; beta-Thalassemia; Blood Transfusion; Child; Deferiprone; Endocri | 2016 |
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
Topics: Administration, Oral; Animals; beta-Thalassemia; Combined Modality Therapy; Deferiprone; Disease Mod | 2015 |
Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress.
Topics: Adolescent; Adult; Antioxidants; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Defer | 2015 |
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver I | 2015 |
Thalassemia major between liver and heart: Where we are now.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferiprone; Deferoxam | 2015 |
Neurological Complications and Cataract in a Child With Thalassemia Major Treated With Deferiprone.
Topics: beta-Thalassemia; Cataract; Cerebellar Ataxia; Child; Deferiprone; Humans; Iron Chelating Agents; Ma | 2015 |
Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; | 2016 |
A Speciation Study on the Perturbing Effects of Iron Chelators on the Homeostasis of Essential Metal Ions.
Topics: beta-Thalassemia; Copper; Deferiprone; Deferoxamine; Humans; Ions; Iron Chelating Agents; Metals; Py | 2015 |
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; D | 2015 |
Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice.
Topics: Animals; Antidotes; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Dextrans; Female; Fib | 2015 |
Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.
Topics: Animals; beta-Thalassemia; Deferiprone; Disease Models, Animal; Erythropoiesis; Iron Chelating Agent | 2016 |
Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Topics: Adolescent; Adult; Audiometry, Pure-Tone; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cros | 2015 |
Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Femal | 2016 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
Therapeutic deferoxamine and deferiprone monitoring in β-thalassemia patients' plasma by field-amplified sample injection and sweeping in capillary electrophoresis.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Electrophoresis, Capillary; Humans; Limit of Detection; | 2016 |
Iron distribution and histopathological study of the effects of deferoxamine and deferiprone in the kidneys of iron overloaded β-thalassemic mice.
Topics: Animals; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Iron; Iron Chelating Age | 2016 |
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; De | 2017 |
Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.
Topics: Benzoates; beta-Thalassemia; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferiprone; Defero | 2017 |
Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Deferiprone; Deferox | 2017 |
Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agent | 2008 |
Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major.
Topics: Adolescent; beta-Thalassemia; Child; Deferiprone; Disease Management; Drug Evaluation; Female; Ferri | 2008 |
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.
Topics: Adolescent; Adult; Anemia; beta-Thalassemia; Bone Marrow Transplantation; Cardiomyopathies; Cause of | 2008 |
High doses of deferiprone may be associated with cerebellar syndrome.
Topics: beta-Thalassemia; Cerebellar Diseases; Child; Deferiprone; Female; Humans; Iron Chelating Agents; Ir | 2009 |
Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.
Topics: Adult; beta-Thalassemia; Cyclic N-Oxides; Deferiprone; Dehydroascorbic Acid; Electron Spin Resonance | 2009 |
Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption.
Topics: Administration, Oral; Adult; beta-Thalassemia; Cataract; Deferiprone; Humans; Iron Chelating Agents; | 2009 |
Oral iron chelation therapy with deferiprone in patients with Thalassemia Major.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferiprone; Female | 2009 |
The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; | 2009 |
Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.
Topics: Adult; beta-Thalassemia; Biomarkers; Circadian Rhythm; Deferiprone; Deferoxamine; Drug Monitoring; D | 2009 |
Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.
Topics: Adolescent; Agranulocytosis; Alveolar Process; beta-Thalassemia; Blood Transfusion; Deferiprone; Dia | 2009 |
The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.
Topics: Benzoates; beta-Thalassemia; Circular Dichroism; Deferasirox; Deferiprone; Hemoglobins; Humans; Iron | 2009 |
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chela | 2009 |
A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Clinical Protocols; | 2009 |
Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Fe | 2009 |
Early cardiac iron overload in children with transfusion-dependent anemias.
Topics: Adolescent; Anemia; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Deferiprone; Defe | 2009 |
Deferiprone chelation therapy for thalassemia major.
Topics: beta-Thalassemia; Deferiprone; Humans; Iron Chelating Agents; Pyridones | 2009 |
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells; | 2010 |
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; | 2010 |
Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice.
Topics: Administration, Oral; Animals; beta-Thalassemia; Collagen; Deferiprone; Dietary Supplements; Ferrous | 2010 |
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Fe | 2010 |
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Defer | 2010 |
Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Fe | 2010 |
Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ec | 2010 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; | 2010 |
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therap | 2010 |
Combined iron chelation therapy.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Combinations; Ferritins; Humans | 2010 |
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug | 2011 |
The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.
Topics: Adult; Agranulocytosis; Antiviral Agents; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, | 2010 |
Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
Topics: Administration, Oral; Adult; Area Under Curve; beta-Thalassemia; Deferiprone; Female; Ferritins; Hem | 2011 |
Quantitative computed tomography is unreliable for measurement of bone mineral density in inadequately chelated adolescent patients with β-thalassemia major: a case-control study.
Topics: Adolescent; Adult; beta-Thalassemia; Bone Density; Case-Control Studies; Child; Deferiprone; Female; | 2011 |
Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
Topics: Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Death; Deferasirox; D | 2010 |
Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.
Topics: beta-Thalassemia; Deferiprone; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Magneti | 2011 |
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Drug Therapy, Combi | 2011 |
Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Deferiprone; Def | 2011 |
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female; | 2011 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasir | 2011 |
Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Chi-Square Distribution; Deferiprone; Deferoxamine; D | 2012 |
Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasi | 2012 |
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferip | 2013 |
Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Topics: Adolescent; Adult; beta-Thalassemia; Body Burden; Child; Deferiprone; Deferoxamine; Drug Therapy, Co | 2013 |
Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
Topics: Adult; Benzoates; beta-Thalassemia; Blood Cell Count; Chelation Therapy; Colony-Forming Units Assay; | 2013 |
Iron-chelation therapy with oral chelators in patients with thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Child, | 2013 |
Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Chi-Square Distribution; Deferipron | 2013 |
Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience.
Topics: Administration, Oral; Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; | 2013 |
Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Liver; Myocardium; | 2002 |
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
Topics: Administration, Oral; Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Echocardiography; Female; | 2002 |
Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators.
Topics: Adolescent; Adult; Antibody Formation; Autoantibodies; beta-Thalassemia; Child; Child, Preschool; De | 2003 |
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Topics: Administration, Oral; beta-Thalassemia; Deferiprone; Deferoxamine; Heart; Humans; Injections, Subcut | 2003 |
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Topics: Animals; beta-Thalassemia; Deferiprone; Deferoxamine; Heart; Humans; Iron Chelating Agents; Liver; P | 2003 |
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyrido | 2003 |
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Half-Life; Humans; Iron; Iron Chelat | 2003 |
Treatment of cardiac iron overload in thalassemia major.
Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Dise | 2003 |
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Disease-Free Survival; Female | 2003 |
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Humans; Iro | 2003 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |
Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Deferiprone; Deferoxamine; Humans; Imm | 2003 |
Introduction to The Olivieri symposium.
Topics: beta-Thalassemia; Bioethical Issues; Blood Transfusion; Canada; Clinical Trials as Topic; Deferipron | 2004 |
Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Female; Humans; Iron Chelating Agents; Join | 2004 |
Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Synergism; Drug Therapy, Combination; Heart | 2005 |
Iron chelation therapy.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Live | 2005 |
Effect of deferiprone on urinary zinc excretion in multiply transfused children with thalassemia major.
Topics: beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferiprone; Female; Humans; Iron Chel | 2005 |
Long-term treatment with deferiprone in a L1 veteran.
Topics: Administration, Oral; Adult; beta-Thalassemia; Deferiprone; Female; Humans; Iron; Iron Chelating Age | 2005 |
Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Def | 2005 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agent | 2005 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: Adolescent; Adult; Agranulocytosis; beta-Thalassemia; Cardiovascular Diseases; Child; Deferiprone; D | 2005 |
Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study.
Topics: Adolescent; Adult; Aspartate Aminotransferases; beta-Thalassemia; Deferiprone; Female; Ferritins; Hu | 2005 |
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Heart Dise | 2006 |
[Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Heart Failure; Humans; Iron C | 2006 |
New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Topics: beta-Thalassemia; Carboxylic Acids; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Design | 2006 |
Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Deferiprone; Drug Therapy, Combination; Humans; Hydrox | 2006 |
Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Failure; Hemosi | 2006 |
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch | 2006 |
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studi | 2006 |
Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Child; Combined Modality T | 2006 |
Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
Topics: Activities of Daily Living; Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Atti | 2006 |
Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
Topics: Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Attitude to Health; beta-Thalass | 2006 |
Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Topics: Adolescent; Adult; Analysis of Variance; beta-Thalassemia; Blood Glucose; Chelation Therapy; Child; | 2006 |
Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Com | 2007 |
Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
Topics: Adult; beta-Thalassemia; Cardiomyopathy, Dilated; Deferiprone; Deferoxamine; Drug Therapy, Combinati | 2007 |
Chelation therapy and bone metabolism markers in thalassemia major.
Topics: Adult; Alkaline Phosphatase; beta-Thalassemia; Bone and Bones; Bone Resorption; Case-Control Studies | 2006 |
[Post transfusionnal iron overload].
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Erythrocyte Transfusion; Humans; Iron Chelati | 2006 |
Severe Henoch-Schönlein purpura in a thalassemic patient under deferiprone treatment.
Topics: Amino Acid Substitution; beta-Thalassemia; Child; Deferiprone; DNA; Familial Mediterranean Fever; Hu | 2008 |
Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
Topics: Adolescent; Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; H | 2007 |
Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Electrocardiography; Female; | 2007 |
Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
Topics: Adult; Agranulocytosis; beta-Thalassemia; Blood Transfusion; Deferiprone; Female; Humans; Intracrani | 2007 |
comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Ferritins; Heart Ventricles; | 2007 |
Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Fe | 2008 |
Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
Topics: Adolescent; Adult; Autoantibodies; B-Lymphocytes; beta-Thalassemia; Chelation Therapy; Child; Deferi | 2008 |
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Def | 2008 |
The labile iron pool in human erythroid cells.
Topics: Antigens, CD; beta-Thalassemia; Bone Marrow Cells; Cells, Cultured; Deferiprone; Erythroblasts; Eryt | 2008 |
Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.
Topics: Adult; Agranulocytosis; Arthritis; beta-Thalassemia; Chemical and Drug Induced Liver Injury; Deferip | 1995 |
An orally active iron chelator.
Topics: Administration, Oral; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron; | 1995 |
Arthropathy in thalassaemia patients receiving deferiprone.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; beta-Thalassemia; Deferiprone; Humans; Iron Chelating Agen | 1994 |
Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Deferiprone; Drug Administration Schedule | 1994 |
Oral iron chelators.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; beta-Thalassemia; Chelating Agents | 1995 |
Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone).
Topics: Adult; Agranulocytosis; Arthritis; beta-Thalassemia; Deferiprone; Female; Humans; Pyridones; Vasculi | 1997 |
Counseling sexually active teenagers treated with potential human teratogens.
Topics: Adolescent; Adolescent Behavior; Anemia, Sickle Cell; beta-Thalassemia; Contraception Behavior; Coun | 1997 |
Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chronic Disease; Deferiprone; Ferritins; Hepatitis C; Humans; I | 1998 |
Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy?
Topics: Administration, Oral; beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron; Iron Overload; Liver; Liv | 1998 |
Constraints of interest: lessons at the Hospital for Sick Children.
Topics: beta-Thalassemia; Biomedical Research; Canada; Clinical Trials as Topic; Conflict of Interest; Contr | 1998 |
Legal issues surrounding privately funded research cause furore in Toronto.
Topics: beta-Thalassemia; Biomedical Research; Canada; Clinical Trials as Topic; Conflict of Interest; Contr | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Liver; Liver Ci | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Liver; Liver Ci | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron Chelating Agents; Iron | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Deferiprone; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Liver Cirr | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Deferiprone; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyr | 1998 |
An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major.
Topics: Adult; Ascorbic Acid; beta-Thalassemia; Deferiprone; Ferritins; Humans; Iron; Iron Chelating Agents; | 1999 |
Bone density and metabolism in thalassaemia.
Topics: Absorptiometry, Photon; Adolescent; Age Determination by Skeleton; Amino Acids; beta-Thalassemia; Bl | 1998 |
Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients.
Topics: Aldehydes; beta-Thalassemia; Biomarkers; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte T | 1999 |
Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
Topics: Adolescent; beta-Thalassemia; Chelating Agents; Child; Deferiprone; Deferoxamine; Humans; Iron Chela | 1999 |
Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey.
Topics: Adolescent; beta-Thalassemia; Chelating Agents; Child; Deferiprone; Deferoxamine; Drug Administratio | 1999 |
Safety profile of the oral iron chelator deferiprone: a multicentre study.
Topics: Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Deferiprone; Gastrointestinal Diseases; Hum | 2000 |
Second HSC researcher sends anonymous 'Olivieri' note. Hospital for Sick Children.
Topics: beta-Thalassemia; Canada; Clinical Trials as Topic; Deferiprone; Drug Approval; Ethics, Medical; Iro | 2000 |
Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
Topics: beta-Thalassemia; Body Height; Bone Diseases; Deferiprone; Deferoxamine; Growth Disorders; Humans; I | 2000 |
Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay.
Topics: Australia; beta-Thalassemia; Blood Transfusion; Chelating Agents; Chlorides; Comet Assay; Deferipron | 2000 |
Free radical formation and oxyhemoglobin oxidation in beta-thalassemic red blood cells in the presence of prooxidants: effects of the free radical scavenger rutin and oral chelator L1.
Topics: beta-Thalassemia; Deferiprone; Erythrocytes; Free Radical Scavengers; Free Radicals; Humans; Iron Ch | 2000 |
L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, hemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassemic patients.
Topics: Antioxidants; beta-Thalassemia; Deferiprone; Deferoxamine; Erythrocytes; Hemoglobins; Humans; Iron C | 2000 |
Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Female; Ferritins; Humans; Iron; Iron Chela | 2000 |
Deferiprone for thalassemia major.
Topics: beta-Thalassemia; Deferiprone; Follow-Up Studies; Humans; Infant, Newborn; Iron; Iron Chelating Agen | 1999 |
Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Ferritins; | 1992 |